PIRP00008494	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00008186	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00001116	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00003268	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00007059	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00003299	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00000812	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00002449	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00008226	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00000440	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00006596	28654860	piR-hsa-15406	piR-hsa-15406	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15406 may correlated with the increased risk of Alzheimer's disease.
PIRP00001173	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00000841	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00002866	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00005017	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00008790	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00005064	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00002580	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00004095	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00000886	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00002232	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00008317	28654860	piR-hsa-11231	piR-hsa-11231	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-11231 may correlated with the increased risk of Alzheimer's disease.
PIRP00005193	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00004871	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00006820	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00008916	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00003697	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00008953	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00006536	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00008146	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00004919	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00006187	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00003264	28654860	piR-hsa-29476	piR-hsa-29476	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29476 may correlated with the increased risk of Alzheimer's disease.
PIRP00006839	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00001892	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00003486	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00007863	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00000654	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00003176	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00005934	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00000956	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00002348	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00005304	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00004057	28654860	piR-hsa-6113	piR-hsa-6113	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-6113 may correlated with the increased risk of Alzheimer's disease.
PIRP00008926	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00008724	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00001647	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00003779	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00007644	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00003828	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00001344	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00002918	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00008763	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00000988	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00007153	28654860	piR-hsa-25985	piR-hsa-25985	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25985 may correlated with the increased risk of Alzheimer's disease.
PIRP00004900	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00004553	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00006527	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00008664	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00003440	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00008781	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00006270	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00007882	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00004616	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00005892	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00002967	28654860	piR-hsa-28116	piR-hsa-28116	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28116 may correlated with the increased risk of Alzheimer's disease.
PIRP00004589	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00004274	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00006329	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00008369	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00003144	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00008482	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00006046	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00007637	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00004325	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00005609	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00002764	28654860	piR-hsa-21636	piR-hsa-21636	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21636 may correlated with the increased risk of Alzheimer's disease.
PIRP00008986	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00008698	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00001614	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00003759	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00007630	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00003804	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00001322	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00002956	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00008746	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00000955	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00007117	28654860	piR-hsa-10710	piR-hsa-10710	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10710 may correlated with the increased risk of Alzheimer's disease.
PIRP00007922	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00007643	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00000471	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00002627	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00006455	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00002770	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00000199	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00001824	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00007677	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00008891	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00005981	28654860	piR-hsa-14962	piR-hsa-14962	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14962 may correlated with the increased risk of Alzheimer's disease.
PIRP00008861	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00003929	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00005530	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00000795	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00002725	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00005241	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00007999	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00003032	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00004392	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00007345	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00006121	28654860	piR-hsa-7193	piR-hsa-7193	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7193 may correlated with the increased risk of Alzheimer's disease.
PIRP00007516	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00007152	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00000023	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00002194	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00005983	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00002313	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00008819	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00001347	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00007204	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00008452	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00005544	28654860	piR-hsa-28390	piR-hsa-28390	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28390 may correlated with the increased risk of Alzheimer's disease.
PIRP00008774	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00008446	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00001358	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00003532	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00007351	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00003625	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00001113	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00002708	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00008492	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00000711	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00006854	28654860	piR-hsa-14119	piR-hsa-14119	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14119 may correlated with the increased risk of Alzheimer's disease.
PIRP00005184	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00004867	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00006885	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00008913	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00003694	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00009027	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00006621	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00008140	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00004914	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00006179	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00003327	28654860	piR-hsa-30892	piR-hsa-30892	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30892 may correlated with the increased risk of Alzheimer's disease.
PIRP00000286	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00009036	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00002068	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00004121	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00007940	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00004233	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00001788	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00003342	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00000026	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00001311	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00007616	28654860	piR-hsa-27725	piR-hsa-27725	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27725 may correlated with the increased risk of Alzheimer's disease.
PIRP00002409	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00002102	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00004133	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00006207	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00000921	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00006316	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00003867	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00005405	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00002140	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00003453	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00000532	28654860	piR-hsa-27489	piR-hsa-27489	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27489 may correlated with the increased risk of Alzheimer's disease.
PIRP00005389	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00000386	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00002025	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00006390	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00008252	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00001691	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00004477	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00008560	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00000833	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00003805	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00002594	28654860	piR-hsa-7759	piR-hsa-7759	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7759 may correlated with the increased risk of Alzheimer's disease.
PIRP00002628	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00006743	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00008315	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00003645	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00005605	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00008023	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00001743	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00005841	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00007291	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00001076	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00008896	28654860	piR-hsa-4445	piR-hsa-4445	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4445 may correlated with the increased risk of Alzheimer's disease.
PIRP00006863	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00006549	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00008515	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00001599	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00005423	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00001658	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00008255	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00000768	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00006606	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00007912	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00004983	28654860	piR-hsa-15247	piR-hsa-15247	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-15247 may correlated with the increased risk of Alzheimer's disease.
PIRP00008137	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00007847	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00000777	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00002896	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00006696	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00002990	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00000501	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00002082	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00007884	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00000072	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00006305	28654860	piR-hsa-21530	piR-hsa-21530	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21530 may correlated with the increased risk of Alzheimer's disease.
PIRP00008973	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00008687	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00001600	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00003746	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00007624	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00003861	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00001306	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00002943	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00008736	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00000951	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00007110	28654860	piR-hsa-14148	piR-hsa-14148	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14148 may correlated with the increased risk of Alzheimer's disease.
PIRP00001202	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00000873	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00002958	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00005053	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00008811	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00005159	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00002671	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00004199	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00000916	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00002258	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00008417	28654860	piR-hsa-13893	piR-hsa-13893	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13893 may correlated with the increased risk of Alzheimer's disease.
PIRP00006032	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00005721	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00007802	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00000748	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00004581	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00000856	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00007573	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00008995	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00005768	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00007068	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00004188	28654860	piR-hsa-27398	piR-hsa-27398	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27398 may correlated with the increased risk of Alzheimer's disease.
PIRP00006034	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00005722	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00007803	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00000750	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00004582	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00000858	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00007574	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00008996	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00005769	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00007069	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00004192	28654860	piR-hsa-27399	piR-hsa-27399	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27399 may correlated with the increased risk of Alzheimer's disease.
PIRP00001768	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00001430	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00003516	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00005576	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00000274	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00005664	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00003246	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00004783	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00001472	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00002810	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00008940	28654860	piR-hsa-27400	piR-hsa-27400	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27400 may correlated with the increased risk of Alzheimer's disease.
PIRP00002157	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00001831	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00003822	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00005944	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00000674	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00005986	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00003553	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00005176	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00001878	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00003187	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00000210	28654860	piR-hsa-23566	piR-hsa-23566	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23566 may correlated with the increased risk of Alzheimer's disease.
PIRP00004048	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00003739	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00005804	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00007883	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00002600	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00007988	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00005537	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00007061	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00003790	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00005110	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00002239	28654860	piR-hsa-13701	piR-hsa-13701	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13701 may correlated with the increased risk of Alzheimer's disease.
PIRP00005785	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00005472	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00007512	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00000489	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00004329	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00000603	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00007259	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00008761	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00005511	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00006783	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00003864	28654860	piR-hsa-19953	piR-hsa-19953	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-19953 may correlated with the increased risk of Alzheimer's disease.
PIRP00008729	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00008405	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00001299	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00003483	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00007311	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00003523	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00001067	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00002657	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00008447	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00000671	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00006819	28654860	piR-hsa-24169	piR-hsa-24169	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-24169 may correlated with the increased risk of Alzheimer's disease.
PIRP00003618	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00003315	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00005366	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00007491	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00002173	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00007594	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00005106	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00006610	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00003360	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00004649	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00001776	28654860	piR-hsa-27138	piR-hsa-27138	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27138 may correlated with the increased risk of Alzheimer's disease.
PIRP00003619	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00003317	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00005367	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00007492	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00002175	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00007596	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00005108	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00006611	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00003362	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00004652	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00001777	28654860	piR-hsa-27139	piR-hsa-27139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27139 may correlated with the increased risk of Alzheimer's disease.
PIRP00003687	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00003396	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00005427	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00007564	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00002246	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00007651	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00005180	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00006689	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00003438	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00004742	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00001835	28654860	piR-hsa-27140	piR-hsa-27140	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27140 may correlated with the increased risk of Alzheimer's disease.
PIRP00003188	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00007389	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00008847	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00004174	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00006141	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00008536	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00002289	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00006392	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00007826	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00001589	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00000443	28654860	piR-hsa-3645	piR-hsa-3645	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-3645 may correlated with the increased risk of Alzheimer's disease.
PIRP00004934	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00009039	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00001584	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00005889	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00007871	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00001270	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00004054	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00008159	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00000426	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00003422	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00002198	28654860	piR-hsa-2038	piR-hsa-2038	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-2038 may correlated with the increased risk of Alzheimer's disease.
PIRP00000915	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00005146	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00006708	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00001944	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00003902	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00006322	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00000014	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00004204	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00005570	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00008414	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00007324	28654860	piR-hsa-8163	piR-hsa-8163	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-8163 may correlated with the increased risk of Alzheimer's disease.
PIRP00004771	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00008873	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00001419	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00005727	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00007726	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00001055	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00003838	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00008009	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00000254	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00003169	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00002046	28654860	piR-hsa-8094	piR-hsa-8094	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8094 may correlated with the increased risk of Alzheimer's disease.
PIRP00004239	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00003915	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00005963	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00008031	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00002806	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00008147	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00005690	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00007251	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00003955	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00005286	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00002403	28654860	piR-hsa-21131	piR-hsa-21131	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21131 may correlated with the increased risk of Alzheimer's disease.
PIRP00001834	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00001496	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00003518	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00005632	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00000356	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00005667	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00003248	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00004858	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00001550	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00002880	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00008945	28654860	piR-hsa-10907	piR-hsa-10907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10907 may correlated with the increased risk of Alzheimer's disease.
PIRP00003870	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00007987	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00000464	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00004894	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00006751	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00000151	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00002968	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00007074	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00008406	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00002314	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00001093	28654860	piR-hsa-6740	piR-hsa-6740	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-6740 may correlated with the increased risk of Alzheimer's disease.
PIRP00004406	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00008480	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00001009	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00005404	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00007388	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00000685	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00003497	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00007646	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00008975	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00002833	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00001601	28654860	piR-hsa-9378	piR-hsa-9378	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9378 may correlated with the increased risk of Alzheimer's disease.
PIRP00007004	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00006693	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00008641	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00001734	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00005547	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00001775	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00008363	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00000892	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00006722	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00008019	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00005109	28654860	piR-hsa-10501	piR-hsa-10501	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-10501 may correlated with the increased risk of Alzheimer's disease.
PIRP00008080	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00007788	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00000726	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00002834	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00006637	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00002935	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00000449	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00002032	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00007839	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00000015	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00006234	28654860	piR-hsa-30713	piR-hsa-30713	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30713 may correlated with the increased risk of Alzheimer's disease.
PIRP00003816	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00003578	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00005559	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00007720	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00002439	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00007747	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00005312	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00006793	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00003617	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00004949	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00001981	28654860	piR-hsa-11988	piR-hsa-11988	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11988 may correlated with the increased risk of Alzheimer's disease.
PIRP00004506	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00008578	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00001123	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00005495	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00007422	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00000771	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00003599	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00007718	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00009006	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00002926	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00001717	28654860	piR-hsa-5959	piR-hsa-5959	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5959 may correlated with the increased risk of Alzheimer's disease.
PIRP00002478	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00002170	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00004203	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00006277	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00001005	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00006401	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00003930	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00005473	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00002215	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00003506	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00000607	28654860	piR-hsa-27491	piR-hsa-27491	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27491 may correlated with the increased risk of Alzheimer's disease.
PIRP00002480	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00002171	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00004207	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00006280	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00001007	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00006403	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00003934	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00005475	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00002216	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00003508	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00000610	28654860	piR-hsa-27492	piR-hsa-27492	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27492 may correlated with the increased risk of Alzheimer's disease.
PIRP00004279	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00008357	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00000880	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00005311	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00007196	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00000570	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00003406	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00007546	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00008813	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00002698	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00001481	28654860	piR-hsa-1580	piR-hsa-1580	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1580 may correlated with the increased risk of Alzheimer's disease.
PIRP00005433	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00005133	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00007096	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00000135	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00003958	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00000238	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00006813	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00008402	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00005185	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00006454	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00003524	28654860	piR-hsa-28187	piR-hsa-28187	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28187 may correlated with the increased risk of Alzheimer's disease.
PIRP00005436	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00005134	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00007098	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00000137	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00003961	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00000240	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00006816	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00008403	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00005188	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00006456	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00003526	28654860	piR-hsa-28188	piR-hsa-28188	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28188 may correlated with the increased risk of Alzheimer's disease.
PIRP00005437	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00005135	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00007100	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00000139	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00003962	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00000242	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00006818	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00008407	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00005190	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00006457	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00003527	28654860	piR-hsa-28189	piR-hsa-28189	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28189 may correlated with the increased risk of Alzheimer's disease.
PIRP00001371	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00001137	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00003133	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00005294	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00009034	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00005335	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00002865	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00004398	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00001174	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00002491	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00008592	28654860	piR-hsa-11726	piR-hsa-11726	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11726 may correlated with the increased risk of Alzheimer's disease.
PIRP00004881	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00004541	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00006503	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00008640	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00003428	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00008683	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00006249	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00007864	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00004585	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00005875	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00002944	28654860	piR-hsa-24221	piR-hsa-24221	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24221 may correlated with the increased risk of Alzheimer's disease.
PIRP00002132	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00001808	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00003794	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00005922	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00000651	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00006035	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00003534	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00005148	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00001856	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00003165	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00000179	28654860	piR-hsa-28771	piR-hsa-28771	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28771 may correlated with the increased risk of Alzheimer's disease.
PIRP00006812	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00006564	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00008528	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00001626	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00005444	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00001672	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00008269	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00000721	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00006627	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00007925	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00004996	28654860	piR-hsa-17896	piR-hsa-17896	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-17896 may correlated with the increased risk of Alzheimer's disease.
PIRP00002126	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00001804	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00003784	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00005916	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00000643	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00005948	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00003529	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00005141	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00001850	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00003155	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00000174	28654860	piR-hsa-24887	piR-hsa-24887	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-24887 may correlated with the increased risk of Alzheimer's disease.
PIRP00002364	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00002116	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00004074	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00006160	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00000868	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00006263	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00003821	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00005360	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00002099	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00003472	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00000480	28654860	piR-hsa-26156	piR-hsa-26156	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26156 may correlated with the increased risk of Alzheimer's disease.
PIRP00003613	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00003306	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00005363	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00007486	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00002163	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00007587	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00005100	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00006605	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00003357	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00004643	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00001772	28654860	piR-hsa-27133	piR-hsa-27133	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27133 may correlated with the increased risk of Alzheimer's disease.
PIRP00003614	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00003308	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00005364	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00007488	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00002166	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00007588	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00005103	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00006608	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00003358	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00004646	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00001773	28654860	piR-hsa-27134	piR-hsa-27134	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27134 may correlated with the increased risk of Alzheimer's disease.
PIRP00000156	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00008904	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00001928	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00003978	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00007827	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00004091	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00001660	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00003190	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00008936	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00001199	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00007483	28654860	piR-hsa-18061	piR-hsa-18061	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-18061 may correlated with the increased risk of Alzheimer's disease.
PIRP00003548	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00003239	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00005237	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00007375	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00002100	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00007520	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00004966	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00006516	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00003280	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00004557	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00001613	28654860	piR-hsa-28908	piR-hsa-28908	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-28908 may correlated with the increased risk of Alzheimer's disease.
PIRP00007756	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00007494	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00000378	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00002486	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00006286	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00002587	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00000108	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00001675	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00007541	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00008753	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00005893	28654860	piR-hsa-30217	piR-hsa-30217	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-30217 may correlated with the increased risk of Alzheimer's disease.
PIRP00008089	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00003205	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00004816	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00009050	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00001993	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00004411	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00007210	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00002308	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00003638	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00006489	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00005388	28654860	piR-hsa-8422	piR-hsa-8422	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-8422 may correlated with the increased risk of Alzheimer's disease.
PIRP00001597	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00001337	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00003366	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00005492	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00000191	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00005531	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00003072	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00004619	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00001394	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00002703	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00008816	28654860	piR-hsa-20485	piR-hsa-20485	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20485 may correlated with the increased risk of Alzheimer's disease.
PIRP00005877	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00000896	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00002519	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00006870	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00008821	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00002204	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00005002	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00009047	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00001421	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00004304	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00003096	28654860	piR-hsa-4300	piR-hsa-4300	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4300 may correlated with the increased risk of Alzheimer's disease.
PIRP00000364	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00000050	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00002066	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00004189	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00008003	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00004230	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00001787	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00003411	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00000090	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00001396	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00007608	28654860	piR-hsa-23848	piR-hsa-23848	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23848 may correlated with the increased risk of Alzheimer's disease.
PIRP00004952	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00008977	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00001513	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00005903	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00007891	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00001209	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00003997	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00008105	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00000437	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00003355	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00002139	28654860	piR-hsa-4685	piR-hsa-4685	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-4685 may correlated with the increased risk of Alzheimer's disease.
PIRP00000104	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00008856	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00001870	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00003937	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00007765	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00004037	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00001587	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00003140	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00008895	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00001154	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00007395	28654860	piR-hsa-27248	piR-hsa-27248	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-27248 may correlated with the increased risk of Alzheimer's disease.
PIRP00000100	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00008854	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00001796	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00003926	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00007754	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00004030	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00001495	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00003126	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00008884	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00001145	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00007312	28654860	piR-hsa-14621	piR-hsa-14621	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-14621 may correlated with the increased risk of Alzheimer's disease.
PIRP00008491	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00008185	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00001115	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00003266	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00007058	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00003375	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00000809	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00002446	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00008224	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00000438	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00006594	28654860	piR-hsa-28025	piR-hsa-28025	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28025 may correlated with the increased risk of Alzheimer's disease.
PIRP00008622	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00008378	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00001288	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00003474	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00007276	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00003496	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00001041	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00002565	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00008426	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00000649	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00006777	28654860	piR-hsa-20271	piR-hsa-20271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20271 may correlated with the increased risk of Alzheimer's disease.
PIRP00003848	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00003543	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00005519	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00007692	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00002402	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00007786	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00005275	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00006834	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00003587	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00004899	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00001942	28654860	piR-hsa-14547	piR-hsa-14547	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-14547 may correlated with the increased risk of Alzheimer's disease.
PIRP00006723	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00006421	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00008367	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00001444	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00005296	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00001556	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00008179	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00000632	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00006458	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00007768	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00004837	28654860	piR-hsa-19112	piR-hsa-19112	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-19112 may correlated with the increased risk of Alzheimer's disease.
PIRP00004752	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00004413	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00006399	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00008505	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00003279	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00008539	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00006114	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00007681	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00004459	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00005738	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00002821	28654860	piR-hsa-25074	piR-hsa-25074	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-25074 may correlated with the increased risk of Alzheimer's disease.
PIRP00000333	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00000025	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00002110	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00004165	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00007986	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00004275	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00001822	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00003379	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00000065	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00001368	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00007641	28654860	piR-hsa-27271	piR-hsa-27271	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27271 may correlated with the increased risk of Alzheimer's disease.
PIRP00003091	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00002805	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00004797	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00006900	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00001642	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00006933	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00004502	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00006091	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00002844	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00004112	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00001168	28654860	piR-hsa-10106	piR-hsa-10106	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-10106 may correlated with the increased risk of Alzheimer's disease.
PIRP00005661	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00005379	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00007482	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00000387	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00004220	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00000492	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00007168	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00008650	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00005415	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00006706	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00003840	28654860	piR-hsa-13408	piR-hsa-13408	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-13408 may correlated with the increased risk of Alzheimer's disease.
PIRP00006295	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00005962	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00007964	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00001019	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00004864	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00001070	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00007714	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00000183	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00006014	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00007339	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00004381	28654860	piR-hsa-29114	piR-hsa-29114	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29114 may correlated with the increased risk of Alzheimer's disease.
PIRP00006013	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00001058	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00002624	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00007017	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00008866	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00002342	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00005137	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00000113	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00001478	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00004450	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00003253	28654860	piR-hsa-5645	piR-hsa-5645	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-5645 may correlated with the increased risk of Alzheimer's disease.
PIRP00006136	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00005831	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00007890	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00000847	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00004696	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00000958	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00007652	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00000034	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00005858	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00007182	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00004291	28654860	piR-hsa-30518	piR-hsa-30518	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-30518 may correlated with the increased risk of Alzheimer's disease.
PIRP00001315	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00001025	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00003017	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00005183	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00008912	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00005222	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00002758	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00004272	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00001080	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00002386	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00008478	28654860	piR-hsa-25652	piR-hsa-25652	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25652 may correlated with the increased risk of Alzheimer's disease.
PIRP00003109	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00002813	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00004873	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00006915	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00001661	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00007029	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00004572	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00006107	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00002853	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00004130	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00001254	28654860	piR-hsa-21497	piR-hsa-21497	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-21497 may correlated with the increased risk of Alzheimer's disease.
PIRP00004781	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00004449	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00006433	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00008538	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00003312	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00008577	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00006148	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00007707	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00004490	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00005783	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00002858	28654860	piR-hsa-11139	piR-hsa-11139	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11139 may correlated with the increased risk of Alzheimer's disease.
PIRP00004920	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00004568	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00006542	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00008677	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00003459	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00008723	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00006282	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00007837	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00004628	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00005904	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00002976	28654860	piR-hsa-16363	piR-hsa-16363	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-16363 may correlated with the increased risk of Alzheimer's disease.
PIRP00008814	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00008571	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00001483	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00003639	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00007517	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00003678	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00001216	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00002778	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00008614	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00000834	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00006998	28654860	piR-hsa-20752	piR-hsa-20752	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20752 may correlated with the increased risk of Alzheimer's disease.
PIRP00008027	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00003068	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00004674	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00008990	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00001852	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00004342	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00007140	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00002176	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00003528	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00006459	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00005278	28654860	piR-hsa-1963	piR-hsa-1963	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-1963 may correlated with the increased risk of Alzheimer's disease.
PIRP00000008	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00007894	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00004658	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00007568	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00004615	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00006358	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00003238	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00003904	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00006450	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00000502	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00003480	28654860	piR-hsa-226	piR-hsa-226	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-226 may correlated with the increased risk of Alzheimer's disease.
PIRP00008457	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00008152	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00001082	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00003235	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00007027	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00003274	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00000770	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00002347	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00008192	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00000408	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00006554	28654860	piR-hsa-16724	piR-hsa-16724	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-16724 may correlated with the increased risk of Alzheimer's disease.
PIRP00003680	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00003391	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00005365	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00007556	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00002241	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00007589	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00005101	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00006687	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00003437	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00004738	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00001774	28654860	piR-hsa-23259	piR-hsa-23259	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23259 may correlated with the increased risk of Alzheimer's disease.
PIRP00005880	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00000898	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00002525	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00006878	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00008768	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00002209	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00005004	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00009051	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00001341	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00004311	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00003101	28654860	piR-hsa-1280	piR-hsa-1280	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1280 may correlated with the increased risk of Alzheimer's disease.
PIRP00005882	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00000899	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00002528	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00006881	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00008770	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00002211	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00005006	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00009052	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00001343	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00004313	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00003104	28654860	piR-hsa-1281	piR-hsa-1281	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1281 may correlated with the increased risk of Alzheimer's disease.
PIRP00005883	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00000900	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00002529	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00006883	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00008773	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00002214	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00005008	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00009055	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00001345	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00004315	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00003105	28654860	piR-hsa-1282	piR-hsa-1282	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-1282 may correlated with the increased risk of Alzheimer's disease.
PIRP00003191	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00002941	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00004956	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00007065	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00001800	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00007106	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00004662	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00006184	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00002986	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00004277	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00001307	28654860	piR-hsa-11907	piR-hsa-11907	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-11907 may correlated with the increased risk of Alzheimer's disease.
PIRP00001525	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00001222	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00003232	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00005368	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00000066	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00005469	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00002946	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00004543	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00001262	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00002567	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00008691	28654860	piR-hsa-28243	piR-hsa-28243	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-28243 may correlated with the increased risk of Alzheimer's disease.
PIRP00008752	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00008498	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00001418	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00003579	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00007418	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00003608	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00001153	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00002678	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00008541	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00000756	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00006921	28654860	piR-hsa-20749	piR-hsa-20749	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-20749 may correlated with the increased risk of Alzheimer's disease.
PIRP00008165	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00007934	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00000814	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00002925	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00006718	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00003025	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00000539	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00002108	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00007917	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00000169	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00006334	28654860	piR-hsa-26293	piR-hsa-26293	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-26293 may correlated with the increased risk of Alzheimer's disease.
PIRP00003196	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00002893	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00004883	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00007006	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00001736	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00007039	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00004584	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00006117	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00002931	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00004212	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00001260	28654860	piR-hsa-25384	piR-hsa-25384	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-25384 may correlated with the increased risk of Alzheimer's disease.
PIRP00004492	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00008573	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00001120	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00005488	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00007414	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00000764	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00003590	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00007713	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00008999	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00002922	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00001709	28654860	piR-hsa-5952	piR-hsa-5952	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-5952 may correlated with the increased risk of Alzheimer's disease.
PIRP00000069	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00004196	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00005790	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00001098	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00002985	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00005483	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00008243	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00003304	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00004656	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00007639	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00006395	28654860	piR-hsa-7681	piR-hsa-7681	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-7681 may correlated with the increased risk of Alzheimer's disease.
PIRP00004575	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00008666	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00001186	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00005579	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00007601	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00000860	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00003672	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00007797	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00000102	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00003001	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00001797	28654860	piR-hsa-9851	piR-hsa-9851	Alzheimer's disease	EFO:0000249	downregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-hsa-9851 may correlated with the increased risk of Alzheimer's disease.
PIRP00000704	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00000388	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00002405	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00004540	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00008318	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00004655	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00002202	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00003715	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00000430	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00001751	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00007901	28654860	piR-hsa-22564	piR-hsa-22564	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-22564 may correlated with the increased risk of Alzheimer's disease.
PIRP00005195	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00004872	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00006822	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00008919	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00003698	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00008956	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00006541	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00008149	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00004921	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00006190	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00003265	28654860	piR-hsa-29478	piR-hsa-29478	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-29478 may correlated with the increased risk of Alzheimer's disease.
PIRP00007560	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00002535	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00004107	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00008470	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00001362	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00003807	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00006583	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00001610	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00003055	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00005905	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00004743	28654860	piR-hsa-4000	piR-hsa-4000	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-4000 may correlated with the increased risk of Alzheimer's disease.
PIRP00001920	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00001588	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00003593	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00005720	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00000434	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00005759	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00003334	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00004950	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00001650	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00002942	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00009033	28654860	piR-hsa-23538	piR-hsa-23538	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-23538 may correlated with the increased risk of Alzheimer's disease.
PIRP00002034	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00001694	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00003737	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00005824	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00000525	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00005913	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00003481	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00005029	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00001739	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00003046	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00000138	28654860	piR-hsa-27438	piR-hsa-27438	Alzheimer's disease	EFO:0000249	upregulation	increased risk	Alzheimer's disease	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Alzheimer's disease was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-hsa-27438 may correlated with the increased risk of Alzheimer's disease.
PIRP00002072	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00006738	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00000360	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00007831	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00009026	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00004046	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00008583	26148798	DQ596390	piR-hsa-26606	Asthma	EFO:0000270	downregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	-0.1	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596390 may correlated with the increased risk of Asthma.
PIRP00000055	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00004794	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00007606	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00005886	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00007178	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00002158	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00006702	26148798	DQ597484	piR-hsa-27730	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597484 may correlated with the increased risk of Asthma.
PIRP00008069	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00003691	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00006412	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00004777	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00006003	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00000991	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00005560	26148798	DQ595186	piR-hsa-25447	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ595186 may correlated with the increased risk of Asthma.
PIRP00004653	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00000226	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00002970	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00001291	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00002577	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00006659	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00002124	26148798	DQ582264	piR-hsa-12487	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ582264 may correlated with the increased risk of Asthma.
PIRP00003562	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00008228	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00001964	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00000273	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00001554	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00005627	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00001117	26148798	DQ597347	piR-hsa-27622	Asthma	EFO:0000270	upregulation	increased risk	asthmatic patientss	N/A	N/A	Akt signaling pathway	0.10	The piRNAs dysregulation associated with Asthma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Asthma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597347 may correlated with the increased risk of Asthma.
PIRP00004970	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00001493	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00007315	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00004049	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00002540	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00006062	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00003714	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00005279	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00000200	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00008795	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00002203	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00001146	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00003439	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00006538	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00004588	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00007000	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	TNFSF4	Cell proliferation and apoptosis 	-0.4	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Bladder carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma. Moreover, both molecular functions and physiological functions of DQ594040 involving in the pathologies of Bladder carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ594040 is possibly correlated with the increased risk of Bladder carcinoma.
PIRP00003513	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00000060	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00005849	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00002616	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00001106	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00004642	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00002305	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00003820	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00007878	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00007408	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00000805	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00008779	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00001991	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00005144	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00003163	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00005563	25305452	DQ585569	piR-hsa-15864	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585569 may correlated with the increased risk of Bladder carcinoma.
PIRP00005626	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00002237	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00007994	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00004785	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00003247	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00006753	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00004425	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00005936	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00000901	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00000407	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00002910	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00001846	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00004099	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00007265	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00005317	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00007667	25305452	DQ580653	piR-hsa-10879	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580653 may correlated with the increased risk of Bladder carcinoma.
PIRP00002432	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00008068	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00004803	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00001523	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00009053	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00003558	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00001193	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00002754	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00006758	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00006294	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00008803	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00007732	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00000874	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00004027	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00002094	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00004478	25305452	DQ598918	piR-hsa-29218	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598918 may correlated with the increased risk of Bladder carcinoma.
PIRP00005218	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00001771	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00007598	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00004309	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00002804	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00006315	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00003957	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00005502	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00000448	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00009019	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00002526	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00001384	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00003659	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00006775	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00004862	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00007256	25305452	DQ585261	piR-hsa-15572	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585261 may correlated with the increased risk of Bladder carcinoma.
PIRP00000670	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00007080	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003207	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00002069	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00007031	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003788	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00001392	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00005585	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00001011	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00002027	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00004456	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00008387	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003039	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00007679	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00005689	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003988	25305452	DQ571000	piR-hsa-1251	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571000 may correlated with the increased risk of Bladder carcinoma.
PIRP00008356	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00005075	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00001679	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00007638	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00005971	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00000424	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00007201	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008693	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00003681	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00003194	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00005712	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00004617	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00006853	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00000908	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008102	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00001348	25305452	DQ598294	piR-hsa-28509	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008064	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00004661	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00001318	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00007215	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00005654	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00000101	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00006757	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00008351	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00003384	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00002886	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00005348	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00004280	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00006531	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00000590	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00007741	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00000959	25305452	DQ595179	piR-hsa-25440	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595179 may correlated with the increased risk of Bladder carcinoma.
PIRP00003010	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00008639	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00005377	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00002145	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00000581	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00004136	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00001727	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00003349	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00007412	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00006867	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00000235	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00008275	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00001468	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00004638	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00002651	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00005016	25305452	DQ587714	piR-hsa-17990	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587714 may correlated with the increased risk of Bladder carcinoma.
PIRP00007640	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00004247	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00000839	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00006761	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00005219	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00008709	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00006387	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00007920	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00002903	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00002401	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00004954	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00003809	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00006059	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00000105	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00007335	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00000547	25305452	DQ584635	piR-hsa-14960	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584635 may correlated with the increased risk of Bladder carcinoma.
PIRP00002645	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00009002	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00005202	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00004019	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00008946	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00005756	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00003468	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00007612	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00002994	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00003963	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00006417	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00001353	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00005021	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00000503	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00007699	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00005953	25305452	DQ575036	piR-hsa-5342	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575036 may correlated with the increased risk of Bladder carcinoma.
PIRP00000614	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00007018	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00003148	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00002018	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00006975	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00003724	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00001409	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00005524	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00000942	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00001954	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00004396	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00008325	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00002974	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00007636	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00005631	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00003939	25305452	DQ577614	piR-hsa-6917	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577614 may correlated with the increased risk of Bladder carcinoma.
PIRP00001884	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00007599	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00004231	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000994	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00008521	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003021	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000647	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00002206	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00006245	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00005747	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00008197	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00007191	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000328	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003510	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00001504	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003931	25305452	DQ580256	piR-hsa-10496	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000736	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00006484	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00003114	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00008988	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00007571	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00001970	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00008596	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00001085	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00005154	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00004733	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00007184	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00006124	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00008350	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00002458	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00000453	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00002831	25305452	DQ591007	piR-hsa-21286	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591007 may correlated with the increased risk of Bladder carcinoma.
PIRP00008083	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00004683	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00001336	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00007236	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00005670	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00000117	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00006773	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00008379	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00003407	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00002906	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00005356	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00004295	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00006553	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00000613	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00007751	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00000984	25305452	DQ589977	piR-hsa-20230	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589977 may correlated with the increased risk of Bladder carcinoma.
PIRP00008954	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00005643	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00002299	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00008187	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00006598	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00001069	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00007815	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00000215	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00004293	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00003808	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00006339	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00005244	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00007547	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00001529	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00008711	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00002003	25305452	DQ600951	piR-hsa-31237	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600951 may correlated with the increased risk of Bladder carcinoma.
PIRP00005761	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00003073	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00008254	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00007145	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00003031	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00008830	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00006534	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00001560	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00006095	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00007083	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00000417	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00004416	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00008097	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00003637	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00001710	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00009037	25305452	DQ575775	piR-hsa-6053	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575775 may correlated with the increased risk of Bladder carcinoma.
PIRP00002785	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00008398	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00005140	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00001896	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000329	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003895	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00001533	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003080	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007139	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00006649	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000071	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00008038	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00001229	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00004391	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00002422	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00004844	25305452	DQ599459	piR-hsa-29716	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000653	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00006410	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00003029	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00008900	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00007367	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00001802	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00008507	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000966	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00005069	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00004544	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00007078	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00005943	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00008207	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00002309	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000367	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00002735	25305452	DQ601548	piR-hsa-31788	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601548 may correlated with the increased risk of Bladder carcinoma.
PIRP00008957	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00005645	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00002301	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00008188	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00006600	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00001072	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00007816	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00000217	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00004294	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00003810	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00006340	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00005246	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00007549	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00001532	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00008714	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00002006	25305452	DQ600952	piR-hsa-31238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600952 may correlated with the increased risk of Bladder carcinoma.
PIRP00002512	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00008219	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00004884	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00001711	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00000074	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00003703	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00001274	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00002838	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00006859	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00006451	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00008867	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00007876	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00001060	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00004187	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00002244	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00004559	25305452	DQ597765	piR-hsa-27995	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ597765 may correlated with the increased risk of Bladder carcinoma.
PIRP00000481	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00006227	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00002881	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00008769	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00007206	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00001646	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00008341	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00000798	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00004904	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00004397	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00006912	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00005801	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00008055	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00002135	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00000204	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00002563	25305452	DQ601526	piR-hsa-31766	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601526 may correlated with the increased risk of Bladder carcinoma.
PIRP00003060	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008689	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005409	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00002265	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00000629	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00004175	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001830	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00003389	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00007480	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00006920	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00000351	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008309	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001501	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00004681	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00002790	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005124	25305452	DQ592938	piR-hsa-23216	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008715	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00005393	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00002030	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00007930	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00006325	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00000832	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00007579	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00009003	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00004012	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00003600	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00006048	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00005041	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00007304	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00001310	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00008429	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00001716	25305452	DQ596932	piR-hsa-27222	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596932 may correlated with the increased risk of Bladder carcinoma.
PIRP00000838	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00006581	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00003228	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000032	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00007592	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00002081	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00008706	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00001164	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00005261	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00004826	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00007280	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00006218	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00008464	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00002554	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000562	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00002928	25305452	DQ600289	piR-hsa-30489	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600289 may correlated with the increased risk of Bladder carcinoma.
PIRP00006449	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00003038	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00008789	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00005577	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00004033	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00007635	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00005200	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00006752	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00001742	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00001234	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00003701	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00002656	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00004962	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00008059	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00006099	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00008413	25305452	DQ589802	piR-hsa-20070	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589802 may correlated with the increased risk of Bladder carcinoma.
PIRP00007015	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00003666	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00000257	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00006208	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00004623	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00008201	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00005805	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00007354	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00002327	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00001888	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00004343	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00003314	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00005569	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00008688	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00006727	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00009028	25305452	DQ596854	piR-hsa-27056	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596854 may correlated with the increased risk of Bladder carcinoma.
PIRP00002782	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00008394	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00005136	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00001890	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00000326	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00003893	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00001526	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00003077	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00007134	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00006644	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00000064	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00008034	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00001226	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00004387	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00002418	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00004842	25305452	DQ599457	piR-hsa-29714	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599457 may correlated with the increased risk of Bladder carcinoma.
PIRP00000291	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00006714	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00002856	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001706	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00006678	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00003458	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001052	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00005179	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00000642	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001654	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00004069	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00008039	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00002665	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00007309	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00005354	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00003646	25305452	DQ577470	piR-hsa-7745	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001741	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00007532	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00004075	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00000909	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00008385	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00002889	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00000493	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00002064	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00006103	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00005607	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00008135	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00007028	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00000186	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00003374	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00001442	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00003795	25305452	DQ584144	piR-hsa-14366	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584144 may correlated with the increased risk of Bladder carcinoma.
PIRP00002784	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00008397	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00005139	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00001893	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00000327	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00003894	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00001530	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00003078	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00007137	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00006646	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00000068	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00008035	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00001228	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00004390	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00002420	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00004843	25305452	DQ599458	piR-hsa-29715	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599458 may correlated with the increased risk of Bladder carcinoma.
PIRP00003511	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00000059	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00005846	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00002614	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00001102	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00004641	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00002303	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00003817	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00007875	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00007406	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00000802	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00008778	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00001989	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00005142	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00003160	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00005562	25305452	DQ585568	piR-hsa-15863	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585568 may correlated with the increased risk of Bladder carcinoma.
PIRP00000669	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00007079	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00003206	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00002067	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00007030	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00003786	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00001391	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00005583	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00001010	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00002026	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00004454	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00008386	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00003033	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00007678	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00005686	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00003985	25305452	DQ570999	piR-hsa-1250	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570999 may correlated with the increased risk of Bladder carcinoma.
PIRP00004915	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00001509	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00007252	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00004065	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00002487	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00006009	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00003667	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005231	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00000147	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00008742	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00002234	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00001105	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00003383	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00006559	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00004614	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00006932	25305452	DQ589140	piR-hsa-19422	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005301	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00001854	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00007669	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00004409	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00002888	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00006414	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00003975	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00005592	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00000537	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00000047	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00002539	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00001467	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00003743	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00006882	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00004957	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00007271	25305452	DQ591143	piR-hsa-20887	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ591143 may correlated with the increased risk of Bladder carcinoma.
PIRP00000586	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00007002	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00003119	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00001990	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00006939	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00003705	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00001293	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00005503	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00000917	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00001929	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00004370	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00008306	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00002955	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00007622	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00005616	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00003917	25305452	DQ570989	piR-hsa-1240	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570989 may correlated with the increased risk of Bladder carcinoma.
PIRP00008512	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00003271	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00002366	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00005674	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00004967	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00007525	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00007382	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00008029	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00000490	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00004969	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00004523	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00002924	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00002435	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00003178	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00004975	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00007081	25305452	DQ570485	piR-hsa-765	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570485 may correlated with the increased risk of Bladder carcinoma.
PIRP00002071	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00007740	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00004339	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00001172	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00008717	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00003200	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00000746	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00002390	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00006362	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00005918	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00008362	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00007379	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00000507	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00003674	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00001715	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00004032	25305452	DQ581967	piR-hsa-12206	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581967 may correlated with the increased risk of Bladder carcinoma.
PIRP00000690	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00006385	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00003065	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00008868	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00007421	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00001842	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00008477	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00001026	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00005105	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00004583	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00007047	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00005992	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00008247	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00002345	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00000335	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00002688	25305452	DQ586986	piR-hsa-17292	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586986 may correlated with the increased risk of Bladder carcinoma.
PIRP00008558	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00005268	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00001857	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00007794	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00006175	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00000687	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00007396	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00008858	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00003869	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00003470	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00005898	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00004888	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00007131	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00001178	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00008278	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00001541	25305452	DQ596918	piR-hsa-27208	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596918 may correlated with the increased risk of Bladder carcinoma.
PIRP00000595	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00007010	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00003134	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00002001	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00006952	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00003712	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00001297	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00005509	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00000928	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00001939	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00004377	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00008311	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00002965	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00007629	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00005624	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00003924	25305452	DQ570996	piR-hsa-1247	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570996 may correlated with the increased risk of Bladder carcinoma.
PIRP00003921	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00000558	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00006276	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00003131	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00001499	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00005083	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00002720	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00004248	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00008271	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00007821	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00001246	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00000111	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00002414	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00005610	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00003652	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00005967	25305452	DQ593888	piR-hsa-22915	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593888 may correlated with the increased risk of Bladder carcinoma.
PIRP00005452	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00002774	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00007952	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00006792	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00002709	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00008514	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00006158	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00001175	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00005773	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00006746	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00000095	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00004073	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00007807	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00003346	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00001361	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00008744	25305452	DQ571849	piR-hsa-2129	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571849 may correlated with the increased risk of Bladder carcinoma.
PIRP00003938	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00000495	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00006303	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00003071	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00001517	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00005102	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00002745	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00004265	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00008287	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00007840	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00001259	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00000130	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00002433	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00005566	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00003663	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00005991	25305452	DQ593538	piR-hsa-23786	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593538 may correlated with the increased risk of Bladder carcinoma.
PIRP00000712	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00006405	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00003084	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00008894	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00007463	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00001866	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00008499	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00001057	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00005118	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00004620	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00007072	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00006016	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00008270	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00002367	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00000362	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00002728	25305452	DQ590181	piR-hsa-20405	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590181 may correlated with the increased risk of Bladder carcinoma.
PIRP00007032	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00003609	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00000272	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00006153	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00004636	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00008150	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00005818	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00007372	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00002335	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00001818	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00004363	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00003263	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00005507	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00008618	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00006740	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00009045	25305452	DQ593358	piR-hsa-23621	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593358 may correlated with the increased risk of Bladder carcinoma.
PIRP00004932	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00001535	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00007263	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00004079	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00002500	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00006021	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00003684	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00005243	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00000161	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00008755	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00002242	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00001121	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00003404	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00006492	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00004634	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00006950	25305452	DQ598409	piR-hsa-28610	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598409 may correlated with the increased risk of Bladder carcinoma.
PIRP00008169	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00005498	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00001607	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00000522	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00005459	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00002233	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00008918	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00003982	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00008496	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00000466	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00002937	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00006891	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00001432	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00006132	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00004113	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00002501	25305452	DQ579020	piR-hsa-9332	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579020 may correlated with the increased risk of Bladder carcinoma.
PIRP00008930	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00006300	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00002430	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00001264	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00006244	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00003014	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00000605	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00004761	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00000214	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00001211	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00003660	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00007673	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00002268	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00006848	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00004955	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00003240	25305452	DQ576917	piR-hsa-7238	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576917 may correlated with the increased risk of Bladder carcinoma.
PIRP00000180	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005923	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00002561	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008462	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00006946	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001404	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008065	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00000496	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00004576	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00004149	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00006615	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005575	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00007851	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001903	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008955	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00002280	25305452	DQ590938	piR-hsa-21217	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590938 may correlated with the increased risk of Bladder carcinoma.
PIRP00007087	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00003731	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00000337	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00006284	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00004702	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00008204	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00005867	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00007458	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00002393	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00001889	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00004422	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00003319	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00005571	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00008692	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00006791	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00000046	25305452	DQ598641	piR-hsa-28841	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ598641 may correlated with the increased risk of Bladder carcinoma.
PIRP00005316	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00001864	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00007676	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00004415	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00002900	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00006424	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00004056	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00005601	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00000554	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00000061	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00002547	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00001479	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00003756	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00006890	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00004968	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00007365	25305452	DQ594556	piR-hsa-24775	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ594556 may correlated with the increased risk of Bladder carcinoma.
PIRP00004751	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00001277	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00007003	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00003843	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00002330	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00005842	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00003456	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00005063	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00008959	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00008569	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00001986	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00000903	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00003203	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00006338	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00004372	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00006704	25305452	DQ596690	piR-hsa-26892	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596690 may correlated with the increased risk of Bladder carcinoma.
PIRP00008396	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00005724	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00001853	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00000755	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00005668	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00002456	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00000103	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00004234	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00008741	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00000708	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00003180	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00007154	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00001690	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00006384	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00004364	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00002741	25305452	DQ579049	piR-hsa-9361	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ579049 may correlated with the increased risk of Bladder carcinoma.
PIRP00007521	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00004094	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00000710	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00006667	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00005078	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00008631	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00006232	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00007789	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00002766	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00002339	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00004814	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00003730	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00005997	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00000041	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00007198	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00000411	25305452	DQ588525	piR-hsa-18837	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588525 may correlated with the increased risk of Bladder carcinoma.
PIRP00004062	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00001367	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00006576	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00005454	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00001305	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00007202	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00004886	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00008914	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00004414	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00005402	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00007848	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00002730	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00006423	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00001962	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00009049	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00007427	25305452	DQ576078	piR-hsa-6341	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576078 may correlated with the increased risk of Bladder carcinoma.
PIRP00004252	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00001548	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00006747	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00005612	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00001492	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00007383	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00004988	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00000040	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00004580	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00005572	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00008002	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00002915	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00006585	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00002136	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00000160	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00007626	25305452	DQ570901	piR-hsa-1152	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570901 may correlated with the increased risk of Bladder carcinoma.
PIRP00007613	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00004194	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00000794	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00006735	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00005174	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00008740	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00006337	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00007872	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00002855	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00002423	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00004901	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00003836	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00006096	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00000136	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00007286	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00000498	25305452	DQ583325	piR-hsa-13634	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583325 may correlated with the increased risk of Bladder carcinoma.
PIRP00007497	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00003998	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00000688	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00006540	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00005058	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00008534	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00006213	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00007757	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00002731	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00002243	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00004784	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00003643	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00005900	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00009007	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00007174	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00000383	25305452	DQ593431	piR-hsa-23679	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593431 may correlated with the increased risk of Bladder carcinoma.
PIRP00007935	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00005276	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00001338	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00000195	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00005227	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00001967	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00008703	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00003742	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00008246	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00000146	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00002605	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00006666	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00001183	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00005815	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00003871	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00002184	25305452	DQ575105	piR-hsa-5411	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575105 may correlated with the increased risk of Bladder carcinoma.
PIRP00005819	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00002471	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00008153	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00005039	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00003436	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00007019	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00004604	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00006129	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00001114	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00000661	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00003149	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00002109	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00004371	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00007570	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00005542	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00007880	25305452	DQ600310	piR-hsa-30510	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600310 may correlated with the increased risk of Bladder carcinoma.
PIRP00000317	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00006068	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00002692	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00008594	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00007022	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00001536	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00008191	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00000644	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00004750	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00004288	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00006742	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00005695	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00007977	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00002053	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00000043	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00002413	25305452	DQ583545	piR-hsa-13825	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ583545 may correlated with the increased risk of Bladder carcinoma.
PIRP00004590	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00001162	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00006934	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00003711	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00002196	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00005717	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00003322	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00004945	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00008909	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00008441	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00001849	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00000773	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00003067	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00006203	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00004243	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00006560	25305452	DQ595292	piR-hsa-25553	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595292 may correlated with the increased risk of Bladder carcinoma.
PIRP00007350	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00003968	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00000583	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00006505	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00004959	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00008436	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00006115	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00007682	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00002610	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00002130	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00004670	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00003551	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00005812	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00008905	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00007050	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00000276	25305452	DQ584252	piR-hsa-14474	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ584252 may correlated with the increased risk of Bladder carcinoma.
PIRP00008584	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00005223	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00001891	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00007749	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00006202	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00000646	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00007437	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00008882	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00003899	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00003434	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00005859	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00004847	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00007086	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00001148	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00008239	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00001581	25305452	DQ580006	piR-hsa-10246	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ580006 may correlated with the increased risk of Bladder carcinoma.
PIRP00006271	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00000963	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00000063	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00003441	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00002658	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00005220	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00005107	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00005765	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00007348	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00002663	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00002261	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00000623	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00000125	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00000872	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00002670	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00004832	25305452	DQ570215	piR-hsa-524	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ570215 may correlated with the increased risk of Bladder carcinoma.
PIRP00005746	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00002349	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00008098	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00004908	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00003367	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00006871	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00004470	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00006060	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00001048	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00000523	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00003013	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00001973	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00004227	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00007402	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00005413	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00007752	25305452	DQ587024	piR-hsa-17330	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ587024 may correlated with the increased risk of Bladder carcinoma.
PIRP00003815	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00001129	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00006323	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00005216	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00001087	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00006914	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00004534	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00008611	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00004142	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00005161	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00007627	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00002469	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00006155	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00001695	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00008808	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00007138	25305452	DQ577347	piR-hsa-7637	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ577347 may correlated with the increased risk of Bladder carcinoma.
PIRP00007621	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00004898	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00000981	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00008889	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00004851	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00001579	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00008321	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00003408	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00007906	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00008848	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00002263	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00006204	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00000803	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00005449	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00003515	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00001801	25305452	DQ575973	piR-hsa-6236	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575973 may correlated with the increased risk of Bladder carcinoma.
PIRP00003653	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00000209	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00006000	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00002800	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00001239	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00004817	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00002452	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00003956	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00008016	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00007584	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00000964	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00008899	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00002141	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00005297	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00003320	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00005698	25305452	DQ585585	piR-hsa-15880	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585585 may correlated with the increased risk of Bladder carcinoma.
PIRP00003353	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00008934	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00005669	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00002464	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00000902	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00004467	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00002060	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00003651	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00007723	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00007229	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00000569	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00008593	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00001805	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00004978	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00002981	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00005343	25305452	DQ581701	piR-hsa-11955	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581701 may correlated with the increased risk of Bladder carcinoma.
PIRP00006661	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00003245	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00008950	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00005772	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00004249	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00007801	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00005378	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00006965	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00001945	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00001428	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00003905	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00002879	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00005151	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00008244	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00006304	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00008608	25305452	DQ590335	piR-hsa-20559	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590335 may correlated with the increased risk of Bladder carcinoma.
PIRP00001887	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00007660	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00004232	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00001088	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00008523	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00003022	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00000648	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00002210	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00006247	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00005750	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00008268	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00007192	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00000332	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00003512	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00001591	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00003933	25305452	DQ601166	piR-hsa-31436	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601166 may correlated with the increased risk of Bladder carcinoma.
PIRP00008381	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00005005	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00001689	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00007593	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00005990	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00000436	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00007127	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00008707	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00003695	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00003214	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00005652	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00004632	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00006868	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00000927	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00008042	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00001290	25305452	DQ590020	piR-hsa-20273	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590020 may correlated with the increased risk of Bladder carcinoma.
PIRP00002152	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00007881	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00004512	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00001308	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00008798	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00003288	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00000905	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00002467	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00006488	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00006011	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00008518	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00007499	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00000602	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00003757	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00001863	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00004195	25305452	DQ601697	piR-hsa-31921	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ601697 may correlated with the increased risk of Bladder carcinoma.
PIRP00000109	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00006502	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00002629	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00001487	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00006471	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00003256	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00000826	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00004979	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00000444	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00001435	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00003891	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00007867	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00002485	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00007088	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00005178	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00003473	25305452	DQ576939	piR-hsa-7260	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576939 may correlated with the increased risk of Bladder carcinoma.
PIRP00002975	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00008606	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00005347	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00002182	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00000542	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00004093	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00001757	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00003301	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00007364	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00006832	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00000268	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00008241	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00001434	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00004591	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00002685	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00005061	25305452	DQ592931	piR-hsa-23209	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592931 may correlated with the increased risk of Bladder carcinoma.
PIRP00004176	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00000738	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00006519	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00003326	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00001785	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00005339	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00002914	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00004513	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00008517	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00008041	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00001423	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00000369	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00002650	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00005800	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00003835	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00006168	25305452	DQ586065	piR-hsa-16315	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ586065 may correlated with the increased risk of Bladder carcinoma.
PIRP00006619	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00003923	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00000027	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00007997	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00003884	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00000630	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00007457	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00002445	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00006942	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00007937	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00001278	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00005350	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00008910	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00004511	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00002559	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00000835	25305452	DQ574993	piR-hsa-5299	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574993 may correlated with the increased risk of Bladder carcinoma.
PIRP00008456	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00005085	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00001758	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00007657	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00006071	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00000511	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00007218	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00008783	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00003768	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00003291	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00005732	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00004717	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00006959	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00001016	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00008123	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00001377	25305452	DQ590028	piR-hsa-20281	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590028 may correlated with the increased risk of Bladder carcinoma.
PIRP00002286	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00008634	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00004813	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00003640	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00008587	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00005383	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00002993	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00007093	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00002598	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00003598	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00006020	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00000895	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00004625	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00000121	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00007313	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00005590	25305452	DQ571998	piR-hsa-2278	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ571998 may correlated with the increased risk of Bladder carcinoma.
PIRP00002092	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00007817	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00004427	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00001255	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00008728	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00003284	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00000829	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00002396	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00006440	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00006002	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00008448	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00007493	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00000597	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00003749	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00001792	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00004115	25305452	DQ599906	piR-hsa-30134	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ599906 may correlated with the increased risk of Bladder carcinoma.
PIRP00007266	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00004507	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00000668	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00008598	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00004458	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00001196	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00007972	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00003002	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00007578	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00008547	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00001937	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00005894	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00000423	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00005165	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00003127	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00001474	25305452	DQ572870	piR-hsa-3178	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ572870 may correlated with the increased risk of Bladder carcinoma.
PIRP00000913	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00007346	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00003471	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00002324	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00007302	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00004028	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00001725	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00005832	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00001257	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00002271	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00004708	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00008718	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00003290	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00007904	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00005937	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00004253	25305452	DQ574835	piR-hsa-5170	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574835 may correlated with the increased risk of Bladder carcinoma.
PIRP00005671	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00002998	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00008176	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00007054	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00002953	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00008775	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00006464	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00001482	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00006010	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00007007	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00000334	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00004336	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00008022	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00003563	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00001617	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00008949	25305452	DQ575764	piR-hsa-6042	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ575764 may correlated with the increased risk of Bladder carcinoma.
PIRP00000837	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00006580	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00003225	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00000030	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00007591	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00002080	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00008704	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00001163	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00005258	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00004825	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00007279	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00006216	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00008461	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00002552	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00000560	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00002927	25305452	DQ600288	piR-hsa-30488	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600288 may correlated with the increased risk of Bladder carcinoma.
PIRP00008460	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00005087	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00001761	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00007658	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00006073	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00000513	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00007219	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00008784	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00003770	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00003293	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00005733	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00004719	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00006961	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00001017	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00008124	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00001379	25305452	DQ590029	piR-hsa-20282	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590029 may correlated with the increased risk of Bladder carcinoma.
PIRP00003170	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00008797	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00005512	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00002302	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00000732	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00004287	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00001872	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00003482	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00007585	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00007035	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00000394	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00008427	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00001635	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00004807	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00002828	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00005175	25305452	DQ590455	piR-hsa-20664	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590455 may correlated with the increased risk of Bladder carcinoma.
PIRP00003857	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00001160	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00006378	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00005251	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00001124	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00006953	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00004564	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00008649	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00004180	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00005205	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00007656	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00002509	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00006194	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00001733	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00008832	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00007188	25305452	DQ576844	piR-hsa-7180	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ576844 may correlated with the increased risk of Bladder carcinoma.
PIRP00001427	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00007103	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003800	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000622	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00008107	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00002574	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00000202	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00001760	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00005814	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00005344	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00007860	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00006725	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00008948	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003063	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00001159	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00003514	25305452	DQ593256	piR-hsa-23519	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593256 may correlated with the increased risk of Bladder carcinoma.
PIRP00002796	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00008479	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00005162	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00001987	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00000346	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00003907	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00001549	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00003087	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00007167	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00006663	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00000080	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00008060	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00001247	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00004469	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00002508	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00004861	25305452	DQ588925	piR-hsa-19207	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588925 may correlated with the increased risk of Bladder carcinoma.
PIRP00008465	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00005090	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00001765	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00007661	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00006076	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00000516	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00007221	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00008788	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00003773	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00003296	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00005737	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00004723	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00006966	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00001022	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00008129	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00001383	25305452	DQ590031	piR-hsa-20284	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590031 may correlated with the increased risk of Bladder carcinoma.
PIRP00002358	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00008712	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00004875	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00003704	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00008659	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00005453	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00003138	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00007246	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00002667	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00003655	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00006093	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00001061	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00004695	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00000188	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00007385	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00005642	25305452	DQ574995	piR-hsa-5301	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ574995 may correlated with the increased risk of Bladder carcinoma.
PIRP00000203	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00005878	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00002581	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00008411	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00006888	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00001334	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00008088	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00000519	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00004596	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00004089	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00006645	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00005518	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00007806	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00001847	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00008981	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00002306	25305452	DQ593621	piR-hsa-23869	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593621 may correlated with the increased risk of Bladder carcinoma.
PIRP00008463	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00005088	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00001763	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00007659	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00006074	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00000514	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00007220	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00008787	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00003772	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00003295	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00005736	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00004721	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00006963	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00001018	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00008126	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00001380	25305452	DQ590030	piR-hsa-20283	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590030 may correlated with the increased risk of Bladder carcinoma.
PIRP00008454	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00005084	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00001755	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00007654	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00006070	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00000508	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00007216	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00008782	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00003767	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00003289	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00005730	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00004715	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00006956	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00001014	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00008121	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00001376	25305452	DQ590027	piR-hsa-20280	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ590027 may correlated with the increased risk of Bladder carcinoma.
PIRP00002677	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00008313	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00004989	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00001810	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00000247	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00003824	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00001388	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00003005	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00006989	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00006545	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00008970	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00007979	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00001158	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00004299	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00002352	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00004687	25305452	DQ596468	piR-hsa-26684	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596468 may correlated with the increased risk of Bladder carcinoma.
PIRP00005077	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00001702	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00007442	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00004245	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00002623	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00006178	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00003834	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00005373	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00000306	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00008874	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00002389	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00001251	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00003535	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00006726	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00004799	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00007105	25305452	DQ589164	piR-hsa-19446	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ589164 may correlated with the increased risk of Bladder carcinoma.
PIRP00003111	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00008751	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00005403	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00002257	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00000686	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00004246	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00001819	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00003452	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00007464	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00006990	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00000340	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00008368	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00001575	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00004759	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00002781	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00005111	25305452	DQ582571	piR-hsa-12794	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ582571 may correlated with the increased risk of Bladder carcinoma.
PIRP00000429	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00006186	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00002825	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00008713	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00007132	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00001668	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00008291	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00000744	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00004845	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00004410	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00006843	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00005821	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00008070	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00002151	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00000148	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00002524	25305452	DQ588363	piR-hsa-18594	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ588363 may correlated with the increased risk of Bladder carcinoma.
PIRP00002676	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00008312	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00004987	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00001807	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00000246	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00003819	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00001386	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00003004	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00006982	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00006543	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00008968	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00007976	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00001156	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00004296	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00002350	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00004685	25305452	DQ596466	piR-hsa-26682	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ596466 may correlated with the increased risk of Bladder carcinoma.
PIRP00000194	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00005876	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00002579	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00008408	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00006886	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00001330	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00008082	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00000515	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00004593	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00004082	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00006638	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00005514	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00007800	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00001840	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00008976	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00002300	25305452	DQ593618	piR-hsa-23866	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ593618 may correlated with the increased risk of Bladder carcinoma.
PIRP00002277	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00007991	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00004622	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00001438	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00008885	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00003416	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00001049	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00002571	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00006631	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00006130	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00008637	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00007607	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00000714	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00003940	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00001992	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00004321	25305452	DQ592048	piR-hsa-22296	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ592048 may correlated with the increased risk of Bladder carcinoma.
PIRP00008286	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00004922	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00001574	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00007501	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00005897	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00000338	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00007025	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00008602	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00003604	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00003100	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00005573	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00004531	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00006759	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00000827	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00007961	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00001207	25305452	DQ595212	piR-hsa-25473	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ595212 may correlated with the increased risk of Bladder carcinoma.
PIRP00001505	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00007212	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00003887	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00000641	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00008189	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00002660	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00000216	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00001848	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00005888	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00005414	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00007877	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00006810	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00009046	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00003162	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00001169	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00003531	25305452	DQ581488	piR-hsa-11773	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ581488 may correlated with the increased risk of Bladder carcinoma.
PIRP00004818	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00001346	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00007165	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00003912	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00002400	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00005912	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00003583	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00005127	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00000062	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00008638	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00002125	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00000990	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00003282	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00006416	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00004455	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00006837	25305452	DQ585211	piR-hsa-15522	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ585211 may correlated with the increased risk of Bladder carcinoma.
PIRP00004337	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00000971	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00006699	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00003542	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00001938	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00005546	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00003130	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00004665	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00008686	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00008263	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00001676	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00000599	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00002907	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00006018	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00004041	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00006406	25305452	DQ600174	piR-hsa-30374	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of DQ600174 may correlated with the increased risk of Bladder carcinoma.
PIRP00004970	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00001493	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00007315	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00004049	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00002540	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00006062	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00003714	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00005279	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00000200	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00008795	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00002203	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00001146	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00003439	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00006538	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00004588	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00007000	25305452	DQ594040	piR-hsa-24274	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ594040 may correlated with the increased risk of Bladder carcinoma.
PIRP00005774	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00002370	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00008043	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00004935	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00003397	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00006899	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00004495	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00006083	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00000979	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00000545	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00003043	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00002002	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00004254	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00007428	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00005426	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00007777	25305452	DQ596307	piR-hsa-26523	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596307 may correlated with the increased risk of Bladder carcinoma.
PIRP00003093	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00006876	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00005972	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00000218	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00008544	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00002042	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00001917	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00002595	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00004150	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00008551	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00008136	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00006530	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00006051	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00006774	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00008564	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00001637	25305452	DQ570392	piR-hsa-672	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570392 may correlated with the increased risk of Bladder carcinoma.
PIRP00005777	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00002371	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00008045	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00004938	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00003398	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00006902	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00004497	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00006086	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00000980	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00000546	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00003045	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00002005	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00004256	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00007430	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00005429	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00007779	25305452	DQ596308	piR-hsa-26524	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596308 may correlated with the increased risk of Bladder carcinoma.
PIRP00005338	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00001972	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00007695	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00004524	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00002923	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00006494	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00004084	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00005622	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00000582	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00000155	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00002626	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00001585	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00003862	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00007009	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00005066	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00007403	25305452	DQ587911	piR-hsa-18158	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587911 may correlated with the increased risk of Bladder carcinoma.
PIRP00005778	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00002374	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00008048	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00004940	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00003399	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00006905	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00004499	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00006088	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00000982	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00000549	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00003047	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00002007	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00004257	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00007431	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00005430	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00007780	25305452	DQ596309	piR-hsa-26525	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596309 may correlated with the increased risk of Bladder carcinoma.
PIRP00000950	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00007386	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00003489	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00002357	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00007333	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00004061	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00001753	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00005856	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00001283	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00002304	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00004756	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00008750	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00003333	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00007928	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00005968	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00004283	25305452	DQ575340	piR-hsa-5632	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575340 may correlated with the increased risk of Bladder carcinoma.
PIRP00003076	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00008721	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00005435	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00002217	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00000655	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00004200	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00001862	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00003419	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00007506	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00006938	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00000376	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00008333	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00001537	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00004714	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00002733	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00005167	25305452	DQ585043	piR-hsa-15354	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585043 may correlated with the increased risk of Bladder carcinoma.
PIRP00005844	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00002440	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00008122	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00004992	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00003469	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00006988	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00004561	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00006166	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00001079	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00000631	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00003103	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00002079	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00004330	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00007536	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00005500	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00007850	25305452	DQ596314	piR-hsa-26530	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596314 may correlated with the increased risk of Bladder carcinoma.
PIRP00005784	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00002380	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00008054	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00004946	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00003403	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00006909	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00004510	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00006097	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00000987	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00000557	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00003052	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00002012	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00004261	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00007445	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00005438	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00007785	25305452	DQ596313	piR-hsa-26529	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596313 may correlated with the increased risk of Bladder carcinoma.
PIRP00000249	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00006679	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00002812	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00001662	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00006628	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00003414	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00001078	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00005211	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00000592	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00001586	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00004026	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00008004	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00002613	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00007254	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00005331	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00003602	25305452	DQ576153	piR-hsa-6416	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ576153 may correlated with the increased risk of Bladder carcinoma.
PIRP00007425	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00004725	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00000789	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00008743	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00004663	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00001403	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00008095	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00003143	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00007742	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00008685	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00002086	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00006025	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00000635	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00005290	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00003351	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00001627	25305452	DQ572042	piR-hsa-2322	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572042 may correlated with the increased risk of Bladder carcinoma.
PIRP00006165	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00002763	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00008423	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00005323	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00003752	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00007318	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00004907	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00006476	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00001363	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00000940	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00003445	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00002391	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00004651	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00007805	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00005817	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00008139	25305452	DQ596354	piR-hsa-26570	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596354 may correlated with the increased risk of Bladder carcinoma.
PIRP00003833	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00000382	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00006185	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00002961	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00001414	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00004985	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00002607	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00004141	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00008183	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00007728	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00001094	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00000022	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00002328	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00005458	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00003490	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00005823	25305452	DQ580466	piR-hsa-10692	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580466 may correlated with the increased risk of Bladder carcinoma.
PIRP00005834	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00002495	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00008172	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00005062	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00003454	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00007040	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00004633	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00006146	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00001126	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00000681	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00003175	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00002123	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00004394	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00007582	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00005561	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00007903	25305452	DQ597622	piR-hsa-27867	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597622 may correlated with the increased risk of Bladder carcinoma.
PIRP00003020	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00008727	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00005380	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00002231	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00000585	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00004140	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00001799	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00003352	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00007416	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00006869	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00000313	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00008281	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00001469	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00004727	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00002750	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00005094	25305452	DQ588954	piR-hsa-19236	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588954 may correlated with the increased risk of Bladder carcinoma.
PIRP00004621	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00001177	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00006962	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00003728	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00002222	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00005735	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00003424	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00004961	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00008924	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00008455	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00001943	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00000791	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00003083	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00006223	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00004263	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00006675	25305452	DQ599177	piR-hsa-29448	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599177 may correlated with the increased risk of Bladder carcinoma.
PIRP00002938	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00008570	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00005321	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00002078	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00000500	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00004055	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00001724	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00003270	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00007323	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00006788	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00000165	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00008206	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00001399	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00004550	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00002586	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00005012	25305452	DQ579883	piR-hsa-10123	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579883 may correlated with the increased risk of Bladder carcinoma.
PIRP00002769	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00008380	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00005117	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00001873	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00000314	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00003883	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00001446	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00003064	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00007120	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00006626	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00009042	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00008030	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00001214	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00004374	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00002407	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00004766	25305452	DQ581096	piR-hsa-11425	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581096 may correlated with the increased risk of Bladder carcinoma.
PIRP00005782	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00002377	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00008052	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00004943	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00003401	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00006907	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00004505	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00006092	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00000985	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00000553	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00003049	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00002009	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00004259	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00007436	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00005434	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00007784	25305452	DQ596311	piR-hsa-26527	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596311 may correlated with the increased risk of Bladder carcinoma.
PIRP00003008	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00008722	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00005372	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00002219	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00000579	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00004132	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00001795	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00003348	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00007410	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00006865	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00000305	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00008272	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00001464	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00004718	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00002737	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00005086	25305452	DQ588949	piR-hsa-19231	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588949 may correlated with the increased risk of Bladder carcinoma.
PIRP00005781	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00002375	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00008050	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00004942	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00003400	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00006906	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00004501	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00006090	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00000983	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00000551	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00003048	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00002008	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00004258	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00007433	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00005432	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00007781	25305452	DQ596310	piR-hsa-26526	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596310 may correlated with the increased risk of Bladder carcinoma.
PIRP00008040	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00004737	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00001295	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00007262	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00005634	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00000154	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00006827	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00008339	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00003361	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00002933	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00005397	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00004338	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00006599	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00000645	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00007793	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00001036	25305452	DQ600079	piR-hsa-30293	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600079 may correlated with the increased risk of Bladder carcinoma.
PIRP00005288	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00001919	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00007663	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00004465	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00002878	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00006409	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00004036	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00005584	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00000531	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00000037	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00002590	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00001458	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00003732	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00006945	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00005003	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00007341	25305452	DQ591874	piR-hsa-22122	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591874 may correlated with the increased risk of Bladder carcinoma.
PIRP00003095	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00006880	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00005977	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00000222	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00008548	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00002045	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00001918	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00002596	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00004153	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00008554	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00008138	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00006533	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00006053	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00006779	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00008567	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00001641	25305452	DQ570394	piR-hsa-674	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570394 may correlated with the increased risk of Bladder carcinoma.
PIRP00002096	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00007820	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00004432	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00001256	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00008730	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00003286	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00000831	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00002399	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00006441	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00006007	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00008450	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00007496	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00000598	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00003751	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00001793	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00004120	25305452	DQ599922	piR-hsa-30136	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599922 may correlated with the increased risk of Bladder carcinoma.
PIRP00005887	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00002488	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00008231	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00005056	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00003503	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00007034	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00004701	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00006210	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00001176	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00000679	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00003244	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00002120	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00004380	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00007580	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00005611	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00007960	25305452	DQ593739	piR-hsa-23987	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593739 may correlated with the increased risk of Bladder carcinoma.
PIRP00002323	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00008024	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00004669	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00001484	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00008923	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00003463	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00001097	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00002611	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00006680	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00006177	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00008694	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00007642	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00000754	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00003914	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00002047	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00004367	25305452	DQ601720	piR-hsa-31944	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601720 may correlated with the increased risk of Bladder carcinoma.
PIRP00006997	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00003642	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00000237	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00006192	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00004587	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00008115	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00005780	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00007329	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00002298	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00001791	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00004327	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00003217	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00005474	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00008658	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00006711	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00009005	25305452	DQ589358	piR-hsa-19640	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589358 may correlated with the increased risk of Bladder carcinoma.
PIRP00008657	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00005976	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00002122	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00000952	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00005929	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00002707	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00000366	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00004509	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00008958	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00000894	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00003378	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00007441	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00001952	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00006544	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00004631	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00002930	25305452	DQ575689	piR-hsa-5967	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ575689 may correlated with the increased risk of Bladder carcinoma.
PIRP00002672	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00009025	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00005221	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00004035	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00008972	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00005786	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00003426	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00007567	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00003019	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00003979	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00006439	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00001294	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00005052	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00000534	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00007719	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00005985	25305452	DQ577740	piR-hsa-7999	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577740 may correlated with the increased risk of Bladder carcinoma.
PIRP00000615	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00006369	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00002984	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00008863	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00007326	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00001832	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00008469	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00000926	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00005024	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00004571	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00007038	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00005975	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00008237	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00002336	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00000322	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00002679	25305452	DQ591460	piR-hsa-21724	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591460 may correlated with the increased risk of Bladder carcinoma.
PIRP00003569	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00000119	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00005907	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00002682	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00001155	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00004722	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00002294	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00003882	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00007933	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00007503	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00000793	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00008823	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00002058	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00005215	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00003234	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00005557	25305452	DQ581730	piR-hsa-11984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581730 may correlated with the increased risk of Bladder carcinoma.
PIRP00001032	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00006698	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00003413	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00000133	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00007729	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00002181	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00008802	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00001321	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00005407	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00004944	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00007401	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00006318	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00008568	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00002634	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00000662	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00003024	25305452	DQ580927	piR-hsa-11256	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ580927 may correlated with the increased risk of Bladder carcinoma.
PIRP00005411	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00002063	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00007770	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00004599	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00002999	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00006518	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00004181	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00005707	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00000673	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00000170	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00002744	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00001606	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00003879	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00007021	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00005147	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00007526	25305452	DQ584405	piR-hsa-14730	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ584405 may correlated with the increased risk of Bladder carcinoma.
PIRP00008951	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00005636	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00002291	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00008182	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00006591	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001132	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00007812	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00000213	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00004286	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00003866	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00006330	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00005315	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00007615	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001604	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00008705	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00001995	25305452	DQ597470	piR-hsa-27716	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597470 may correlated with the increased risk of Bladder carcinoma.
PIRP00008645	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00005346	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00001961	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00007879	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00006266	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00000707	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00007527	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00008935	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00003954	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00003479	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00005995	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00004918	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00007173	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00001203	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00008364	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00001666	25305452	DQ597858	piR-hsa-28088	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597858 may correlated with the increased risk of Bladder carcinoma.
PIRP00005641	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00002256	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00008007	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00004812	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00003269	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00006760	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00004453	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00005952	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00000923	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00000428	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00002983	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00001867	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00004127	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00007298	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00005385	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00007735	25305452	DQ593702	piR-hsa-23950	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593702 may correlated with the increased risk of Bladder carcinoma.
PIRP00004732	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00002039	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00007235	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00006142	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00001977	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00007828	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00005493	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00000491	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00005067	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00006085	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00008504	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00003444	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00007046	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00002639	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00000627	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00008087	25305452	DQ579146	piR-hsa-9444	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ579146 may correlated with the increased risk of Bladder carcinoma.
PIRP00006281	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00002884	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00008537	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00005418	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00003878	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00007481	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00005023	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00006595	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00001486	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00001090	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00003550	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00002505	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00004788	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00007911	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00005921	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00008251	25305452	DQ582426	piR-hsa-12649	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582426 may correlated with the increased risk of Bladder carcinoma.
PIRP00002847	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00006618	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00005711	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00009014	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00008277	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00001747	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00001645	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00002343	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00003889	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00008283	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00007889	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00006274	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00005792	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00006515	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00008289	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00001340	25305452	DQ570324	piR-hsa-180	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570324 may correlated with the increased risk of Bladder carcinoma.
PIRP00005359	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00001933	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00007724	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00004475	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00002947	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00006475	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00004126	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00005651	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00000620	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00000116	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00002668	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00001542	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00003831	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00006968	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00005020	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00007454	25305452	DQ585286	piR-hsa-15597	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585286 may correlated with the increased risk of Bladder carcinoma.
PIRP00008969	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00005658	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00002316	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00008198	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00006614	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00001084	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00007825	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00000229	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00004308	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00003818	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00006359	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00005269	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00007565	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00001546	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00008726	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00002021	25305452	DQ598373	piR-hsa-28588	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598373 may correlated with the increased risk of Bladder carcinoma.
PIRP00003967	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00000533	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00006258	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00003098	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00001559	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00005131	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00002683	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00004290	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00008258	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00007862	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00001224	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00000163	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00002463	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00005597	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00003626	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00005947	25305452	DQ596111	piR-hsa-26343	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596111 may correlated with the increased risk of Bladder carcinoma.
PIRP00005362	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00001935	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00007725	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00004476	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00002950	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00006477	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00004129	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00005653	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00000621	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00000118	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00002669	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00001545	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00003832	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00006971	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00005022	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00007456	25305452	DQ585287	piR-hsa-15598	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585287 may correlated with the increased risk of Bladder carcinoma.
PIRP00007505	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00004078	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00000693	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00006655	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00005071	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00008617	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00006224	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00007776	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00002749	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00002329	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00004802	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00003717	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00005974	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00000029	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00007181	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00000397	25305452	DQ597293	piR-hsa-27568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597293 may correlated with the increased risk of Bladder carcinoma.
PIRP00005820	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00003137	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00008300	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00007208	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00003079	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00008872	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00006512	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00001632	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00006145	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00007142	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00000463	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00004466	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00008148	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00003692	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00001752	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00000028	25305452	DQ571055	piR-hsa-1306	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571055 may correlated with the increased risk of Bladder carcinoma.
PIRP00002360	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00008000	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00004720	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00001451	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00008965	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00003485	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00001064	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00002654	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00006709	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00006215	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00008656	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00007674	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00000790	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00003950	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00002015	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00004335	25305452	DQ589839	piR-hsa-20107	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ589839 may correlated with the increased risk of Bladder carcinoma.
PIRP00004092	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00001408	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00006613	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00005480	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00001339	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00007232	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00004924	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00008944	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00004447	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00005422	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00007866	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00002837	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00006447	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00001997	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00000021	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00007485	25305452	DQ574685	piR-hsa-5020	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574685 may correlated with the increased risk of Bladder carcinoma.
PIRP00007531	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00004806	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00000876	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00008812	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00004760	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00001471	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00008167	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00003223	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00007819	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00008765	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00002149	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00006113	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00000706	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00005353	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00003431	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00001712	25305452	DQ572051	piR-hsa-2331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572051 may correlated with the increased risk of Bladder carcinoma.
PIRP00006036	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00003377	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00008525	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00007479	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00003331	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00000051	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00006750	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00001861	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00006389	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00007392	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00000698	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00004712	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00008352	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00003916	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00002000	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00000251	25305452	DQ571328	piR-hsa-1331	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571328 may correlated with the increased risk of Bladder carcinoma.
PIRP00006029	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00002609	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00008292	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00005199	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00003629	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00007190	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00004776	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00006361	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00001250	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00000811	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00003307	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00002269	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00004526	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00007688	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00005673	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00008018	25305452	DQ582387	piR-hsa-12610	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582387 may correlated with the increased risk of Bladder carcinoma.
PIRP00006167	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00002767	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00008425	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00005326	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00003755	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00007320	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00004911	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00006478	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00001366	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00000943	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00003448	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00002392	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00004654	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00007810	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00005822	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00008144	25305452	DQ596356	piR-hsa-26572	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596356 may correlated with the increased risk of Bladder carcinoma.
PIRP00000820	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00007250	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00003376	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00002238	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00007209	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00003944	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00001547	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00005729	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00001166	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00002179	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00004608	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00008546	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00003193	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00007823	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00005855	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00004156	25305452	DQ571021	piR-hsa-1272	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571021 may correlated with the increased risk of Bladder carcinoma.
PIRP00001567	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00007334	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00003928	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000753	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00008234	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00002723	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000342	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00001902	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00005935	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00005465	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00007996	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00006856	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000036	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00003211	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00001285	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00003635	25305452	DQ598548	piR-hsa-28749	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ598548 may correlated with the increased risk of Bladder carcinoma.
PIRP00000220	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00006652	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00002780	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00001609	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00006582	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003371	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000945	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00005095	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000563	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00001553	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003987	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007975	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00002588	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007228	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00005287	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003567	25305452	DQ577459	piR-hsa-7734	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000499	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00006191	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00002830	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008720	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00007225	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00001671	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008294	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00000819	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00004850	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00004412	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00006850	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00005825	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00008078	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00002155	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00000153	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00002530	25305452	DQ582294	piR-hsa-12517	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ582294 may correlated with the increased risk of Bladder carcinoma.
PIRP00000012	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00006428	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00002546	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00001389	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00006386	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00003145	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00000725	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00004877	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00000258	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00001320	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00003781	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00007772	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00002320	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00006994	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00004994	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00003365	25305452	DQ578335	piR-hsa-8576	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ578335 may correlated with the increased risk of Bladder carcinoma.
PIRP00000785	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00006468	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00003090	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00008967	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00007551	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00001958	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00008580	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00001133	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00005132	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00004703	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00007172	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00006102	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00008338	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00002443	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00000442	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00002818	25305452	DQ596282	piR-hsa-26498	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596282 may correlated with the increased risk of Bladder carcinoma.
PIRP00002824	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00000091	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005341	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00004170	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00000045	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005899	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00003533	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00007722	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00003147	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00004111	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00006546	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00001437	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005177	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00000663	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00007841	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00006125	25305452	DQ571140	piR-hsa-1477	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ571140 may correlated with the increased risk of Bladder carcinoma.
PIRP00005291	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00002578	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00007796	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00006648	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00002538	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00008337	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00005966	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00001000	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00005600	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00006574	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00008971	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003909	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00007655	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00003154	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00001192	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00008563	25305452	DQ577000	piR-hsa-7319	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577000 may correlated with the increased risk of Bladder carcinoma.
PIRP00005523	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00002113	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00007886	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00004657	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00003118	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00006669	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00004236	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00005837	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00000781	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00000285	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00002799	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00001737	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00003981	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00007158	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00005206	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00007572	25305452	DQ586998	piR-hsa-17304	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ586998 may correlated with the increased risk of Bladder carcinoma.
PIRP00004025	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00000667	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00006400	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00003250	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00001631	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00005273	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00002836	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00004356	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00008376	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00007983	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00001335	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00000287	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00002584	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00005718	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00003747	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00006087	25305452	DQ591339	piR-hsa-21604	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591339 may correlated with the increased risk of Bladder carcinoma.
PIRP00000705	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00006397	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00003012	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00008886	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00007449	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00001860	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00008497	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00001051	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00005055	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00004613	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00007063	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00006012	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00008264	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00002363	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00000355	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00002721	25305452	DQ581827	piR-hsa-12081	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581827 may correlated with the increased risk of Bladder carcinoma.
PIRP00001136	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00006766	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00003500	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00000234	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00007834	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00002287	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00008888	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00001441	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00005508	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00005043	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00007542	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00006436	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00008671	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00002779	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00000759	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00003136	25305452	DQ581440	piR-hsa-11725	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ581440 may correlated with the increased risk of Bladder carcinoma.
PIRP00008878	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005578	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00002213	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008113	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00006500	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00000961	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00007733	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00000140	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00004211	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00003713	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00006251	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00005171	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00007451	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001447	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00008616	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001909	25305452	DQ600938	piR-hsa-31224	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600938 may correlated with the increased risk of Bladder carcinoma.
PIRP00001109	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00004917	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00003974	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00007343	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00006555	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00009054	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00008933	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00000576	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00002165	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00006558	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00006140	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00004547	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00004045	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00004824	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00006571	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00008696	25305452	DQ570657	piR-hsa-922	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ570657 may correlated with the increased risk of Bladder carcinoma.
PIRP00006336	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003649	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00008818	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007727	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00003601	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000331	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007049	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00002098	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00006674	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00007685	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000999	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00005000	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00008648	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00004206	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00002285	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00000548	25305452	DQ572459	piR-hsa-2695	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ572459 may correlated with the increased risk of Bladder carcinoma.
PIRP00006335	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00002989	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00008665	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00005539	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00003922	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00007597	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00005145	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00006662	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00001620	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00001187	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00003658	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00002608	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00004913	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00008017	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00006045	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00008355	25305452	DQ583718	piR-hsa-13984	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ583718 may correlated with the increased risk of Bladder carcinoma.
PIRP00005606	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00002932	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00008111	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00006981	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00002892	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00008695	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00006327	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00001328	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00005928	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00006924	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00000255	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00004260	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00007951	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00003495	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00001531	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00008881	25305452	DQ577543	piR-hsa-7817	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ577543 may correlated with the increased risk of Bladder carcinoma.
PIRP00001453	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00007868	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00003970	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00002859	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00007832	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00004569	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00002276	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00006377	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00001803	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00002876	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00005257	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00000159	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00003814	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00008471	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00006483	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00004882	25305452	DQ574109	piR-hsa-4371	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ574109 may correlated with the increased risk of Bladder carcinoma.
PIRP00005704	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00002383	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00008062	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00004951	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00003335	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00006916	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00004517	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00006022	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00000993	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00000566	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00003057	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00002020	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00004269	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00007455	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00005445	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00007791	25305452	DQ597100	piR-hsa-27390	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597100 may correlated with the increased risk of Bladder carcinoma.
PIRP00005706	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00002385	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00008063	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00004953	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00003340	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00006919	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00004520	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00006023	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00000996	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00000567	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00003059	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00002024	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00004270	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00007462	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00005447	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00007792	25305452	DQ597101	piR-hsa-27391	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597101 may correlated with the increased risk of Bladder carcinoma.
PIRP00000324	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00006075	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00002706	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00008603	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00007026	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00001466	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00008196	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00000650	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00004753	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00004224	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00006745	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00005629	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00007919	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00001982	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00000054	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00002417	25305452	DQ601506	piR-hsa-31746	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601506 may correlated with the increased risk of Bladder carcinoma.
PIRP00004297	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00000935	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00006672	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00003509	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00001901	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00005443	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00003085	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00004630	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00008643	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00008163	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00001630	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00000488	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00002803	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00005910	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00004015	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00006368	25305452	DQ601450	piR-hsa-31691	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601450 may correlated with the increased risk of Bladder carcinoma.
PIRP00007400	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00004008	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00000626	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00006550	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00004982	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00008474	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00006152	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00007708	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00002647	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00002178	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00004716	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00003586	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00005840	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00008929	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00007085	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00000316	25305452	DQ600790	piR-hsa-31076	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ600790 may correlated with the increased risk of Bladder carcinoma.
PIRP00006058	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00002727	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00008400	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00005289	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00003662	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00007294	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00004879	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00006396	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00001331	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00000912	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00003427	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00002365	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00004627	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00007775	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00005789	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00008117	25305452	DQ597651	piR-hsa-27896	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597651 may correlated with the increased risk of Bladder carcinoma.
PIRP00001833	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00007557	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00004182	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00001031	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00008483	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00002972	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00000601	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00002161	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00006198	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00005697	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00008223	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00007130	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00000280	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00003475	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00001538	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00003892	25305452	DQ593305	piR-hsa-23568	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593305 may correlated with the increased risk of Bladder carcinoma.
PIRP00007381	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00003986	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00000609	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00006532	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00004977	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00008524	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00006135	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00007696	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00002625	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00002240	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00004694	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00003632	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00005891	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00008998	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00007076	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00000299	25305452	DQ599994	piR-hsa-30208	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ599994 may correlated with the increased risk of Bladder carcinoma.
PIRP00004282	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00000911	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00006651	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00003491	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00001882	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00005491	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00003070	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00004607	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00008626	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00008213	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00001603	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00000541	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00002850	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00005956	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00003993	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00006349	25305452	DQ588688	piR-hsa-18985	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ588688 may correlated with the increased risk of Bladder carcinoma.
PIRP00001749	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00007467	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00004090	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000925	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00008401	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00002905	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000506	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00002089	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00006119	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00005615	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00008145	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00007045	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000198	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00003394	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00001452	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00003812	25305452	DQ593289	piR-hsa-23552	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593289 may correlated with the increased risk of Bladder carcinoma.
PIRP00000483	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00006229	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00002883	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00008772	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00007207	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00001649	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00008343	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00000801	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00004906	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00004402	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00006913	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00005802	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00008058	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00002138	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00000206	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00002564	25305452	DQ601527	piR-hsa-31767	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ601527 may correlated with the increased risk of Bladder carcinoma.
PIRP00001965	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00007712	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00004306	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00001149	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00008604	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00003174	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00000720	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00002284	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00006321	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00005890	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00008332	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00007338	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00000479	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00003648	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00001686	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00004001	25305452	DQ597696	piR-hsa-27926	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597696 may correlated with the increased risk of Bladder carcinoma.
PIRP00002543	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00008180	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00004923	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00001674	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00000107	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00003670	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00001244	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00002867	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00006898	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00006419	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00008839	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00007846	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00001006	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00004151	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00002199	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00004532	25305452	DQ585901	piR-hsa-16151	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ585901 may correlated with the increased risk of Bladder carcinoma.
PIRP00008486	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00005197	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00001790	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00007731	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00006109	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00000538	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00007317	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00008805	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00003806	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00003325	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00005839	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00004755	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00006995	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00001059	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00008217	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00001470	25305452	DQ597833	piR-hsa-28063	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ597833 may correlated with the increased risk of Bladder carcinoma.
PIRP00004483	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00001066	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00006749	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00003607	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00002097	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00005608	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00003204	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00004820	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00008758	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00008324	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00001740	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00000672	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00002964	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00006098	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00004124	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00006462	25305452	DQ596660	piR-hsa-26862	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596660 may correlated with the increased risk of Bladder carcinoma.
PIRP00006951	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00003547	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00000205	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00006077	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00004549	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00008085	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00005734	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00007293	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00002267	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00001750	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00004281	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00003182	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00005441	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00008553	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00006686	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00008960	25305452	DQ593354	piR-hsa-23617	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ593354 may correlated with the increased risk of Bladder carcinoma.
PIRP00004047	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00000628	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00006353	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00003195	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00001667	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00005225	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00002795	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00004386	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00008330	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00007938	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00001292	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00000244	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00002545	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00005666	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00003708	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00006041	25305452	DQ596128	piR-hsa-26359	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596128 may correlated with the increased risk of Bladder carcinoma.
PIRP00001969	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00007666	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00004322	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00001096	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00008610	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00003088	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00000659	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00002293	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00006332	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00005835	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00008274	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00007264	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00000416	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00003589	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00001602	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00003943	25305452	DQ587101	piR-hsa-17407	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ587101 may correlated with the increased risk of Bladder carcinoma.
PIRP00004105	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00000741	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00006463	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00003339	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00001718	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00005345	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00002920	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00004440	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00008459	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00008051	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00001429	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00000370	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00002659	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00005810	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00003841	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00006173	25305452	DQ591351	piR-hsa-21616	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ591351 may correlated with the increased risk of Bladder carcinoma.
PIRP00005683	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00002292	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00007985	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00004849	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00003305	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00006824	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00004418	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00006006	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00000891	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00000465	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00002960	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00001916	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00004171	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00007337	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00005361	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00007711	25305452	DQ596300	piR-hsa-26516	Bladder carcinoma	EFO:0000292	downregulation	increased risk	bladder cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of DQ596300 may correlated with the increased risk of Bladder carcinoma.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00005580	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00003777	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00007963	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00003429	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00004401	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00001719	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00005417	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00000922	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00006394	29382334	piR-1245	piR-hsa-1963	Bladder carcinoma	EFO:0000292	upregulation	increased risk	bladder cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Bladder carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Bladder carcinoma.
PIRP00003725	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00007700	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00004482	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00005319	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00000236	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00005272	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00000432	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00002023	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00005337	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00002638	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00002438	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00007897	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00003908	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00008101	27414029	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	decreased risk	breast cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Breast carcinoma.
PIRP00005757	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00000604	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00006486	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007336	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00002315	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007281	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00002494	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00004022	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007357	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00004693	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00004464	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00000813	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00005926	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00001068	27414029	piR-823	piR-hsa-1282	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell line which was malignant	N/A	N/A	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00001276	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00001075	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00002230	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007595	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000225	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00001960	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00005499	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007990	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000954	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007548	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00006682	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00001189	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000243	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00006948	25779046	pi-sno75	pi-sno75	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cells	N/A	TRAIL	hCOMPASS-like complexes	-0.8	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of pi-sno75 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of pi-sno75 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the pi-sno75 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the downregulation of pi-sno75 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00008390	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00005425	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00003873	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00006404	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00008893	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007461	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000459	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00001865	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00002827	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007157	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000263	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00007234	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00000361	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00001161	26210741	piR-021285	piR-hsa-29509	Breast carcinoma	EFO:0000305	rs1326306	increased risk	breast cancer	N/A	N/A	Cell proliferation and EMT signaling pathway	-0.4	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the rs1326306 of piR-021285 may correlated with the increased risk of Breast carcinoma. Moreover, both molecular functions and physiological functions of piR-021285 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs1326306 of piR-021285 is possibly correlated with the increased risk of Breast carcinoma.
PIRP00003173	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00000143	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00007721	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00001135	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00003683	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00002164	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00004312	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00005677	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00006548	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00001812	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00004110	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00001895	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00004198	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00005015	25313140	DQ596670	piR-hsa-26872	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596670 may correlated with the increased risk of Breast carcinoma.
PIRP00005741	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00002777	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00001195	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00003799	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00006348	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00004772	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00006974	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00008262	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00000112	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00004474	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00006755	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00004548	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00006851	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00007687	25313140	DQ598183	piR-hsa-28398	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598183 may correlated with the increased risk of Breast carcinoma.
PIRP00002103	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00008161	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00006701	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00000110	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00002675	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00001091	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00003332	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00004706	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00005564	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00000783	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00003123	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00000861	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00003220	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00003977	25313140	DQ597341	piR-hsa-27616	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ597341 may correlated with the increased risk of Breast carcinoma.
PIRP00001957	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00008026	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00006481	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00009030	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00002548	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00000918	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00003185	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00004480	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00005421	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00000657	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00002980	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00000724	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00003066	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00003856	25313140	DQ598252	piR-hsa-28467	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ598252 may correlated with the increased risk of Breast carcinoma.
PIRP00004389	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00001375	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00008871	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00002377	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00004943	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00003401	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00005540	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00006907	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00007804	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00003049	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00005351	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00003108	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00005434	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00006209	25313140	DQ596311	piR-hsa-26527	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of DQ596311 may correlated with the increased risk of Breast carcinoma.
PIRP00005920	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00002949	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00001382	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00003972	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00006508	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00004964	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00007177	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00008442	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00000293	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00004678	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00006970	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00004763	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00007053	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00007853	25313140	DQ598677	piR-hsa-28877	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ598677 may correlated with the increased risk of Breast carcinoma.
PIRP00003628	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00000625	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00008157	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00001688	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00004225	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00002615	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00004880	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00006164	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00007109	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00002376	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00004680	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00002441	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00004775	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00005545	25313140	DQ597960	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ597960 may correlated with the increased risk of Breast carcinoma.
PIRP00005460	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00000279	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00006193	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00007008	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00001999	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00006947	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00002183	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00003710	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00007024	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00004376	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00004139	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00000494	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00005621	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00000727	25313140	DQ570994	piR-hsa-1245	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ570994 may correlated with the increased risk of Breast carcinoma.
PIRP00003628	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00000625	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00008157	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00001688	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00004225	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00002615	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00004880	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00006164	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00007109	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00002376	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00004680	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00002441	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00004775	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00005545	27289065	piR-36026	piR-hsa-28175	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	MCF-7 breast cancer cell line	N/A	SERPINA1; LRAT; Caspase-3	Cell appoptosis	0.80	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-36026 may correlated with the increased risk and poor progonosis of Breast carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-36026 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-36026 dysregulation associated with the pathologies of Breast carcinoma. Altogether, all above results suggested that the upregulation of piR-36026 is possibly correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00007913	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00002789	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00008623	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00004637	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00000373	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00006593	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00002979	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00003216	29382334	piR-1245	piR-hsa-1963	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Breast carcinoma.
PIRP00005256	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00002255	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00000734	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00003287	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00005829	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00004218	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00006448	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00007845	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00008676	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00003946	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00006255	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00004018	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00006352	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00007141	28423657	piR-34871	piR-hsa-27007	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34871 may correlated with the increased risk of Breast carcinoma.
PIRP00002017	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00008077	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00006521	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00009010	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00002532	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00000976	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00003161	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00004533	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00005476	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00000701	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00002966	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00000767	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00003058	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00003837	28423657	piR-52200	piR-hsa-15399	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52200 may correlated with the increased risk of Breast carcinoma.
PIRP00003990	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00001004	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00008586	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00002065	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00004603	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00003000	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00005263	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00006604	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00007543	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00002748	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00005068	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00002823	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00005149	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00005902	28423657	piR-35127	piR-hsa-27351	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35127 may correlated with the increased risk of Breast carcinoma.
PIRP00001284	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00005274	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00002062	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00002870	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00006910	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00002826	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00007107	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00008620	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00002898	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00000190	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00009031	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00005400	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00001398	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00005665	28423657	piR-46545	piR-hsa-8674	Breast carcinoma	EFO:0000305	downregulation	increased risk	breast cancer cell lines	N/A	N/A	AMPK signaling pathway	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-46545 may correlated with the increased risk of Breast carcinoma.
PIRP00008754	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00003631	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00000415	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00001237	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00005336	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00001185	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00005496	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00007043	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00001258	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00007717	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00007533	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00003771	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00008908	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00004060	23229900	piR-4987	piR-hsa-7193	Breast carcinoma	EFO:0000305	upregulation	increased risk and poor progonosis	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-4987 may correlated with the increased risk and poor progonosis of Breast carcinoma.
PIRP00003776	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00000763	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00008293	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00001829	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00004385	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00002794	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00005034	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00006313	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00007269	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00002521	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00004841	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00002583	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00004941	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00005676	23229900	piR-20365	piR-hsa-28190	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20365 may correlated with the increased risk of Breast carcinoma.
PIRP00005588	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00002593	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00001054	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00003630	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00006180	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00004577	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00006787	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00008106	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00009018	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00004310	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00006617	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00004400	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00006705	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00007554	23229900	piR-20485	piR-hsa-28374	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20485 may correlated with the increased risk of Breast carcinoma.
PIRP00007171	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00004155	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00002603	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00005226	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00007753	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00006138	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00008340	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00000578	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00001521	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00005866	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00008166	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00005932	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00008249	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00009012	23229900	piR-20582	piR-hsa-28527	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-20582 may correlated with the increased risk of Breast carcinoma.
PIRP00000735	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00006833	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00005381	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00007900	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00001327	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00008810	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00001998	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00003387	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00004229	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00008533	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00001794	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00008612	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00001881	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00002662	23229900	piR-19825	piR-hsa-27493	Breast carcinoma	EFO:0000305	upregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-19825 may correlated with the increased risk of Breast carcinoma.
PIRP00008917	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00005965	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00004439	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00006940	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00000396	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00007969	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00001056	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00002436	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00003309	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00007670	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00000830	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00007787	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00000919	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00001729	23229900	piR-17458	piR-hsa-24360	Breast carcinoma	EFO:0000305	downregulation	increased risk	resected breast cancer cases	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-17458 may correlated with the increased risk of Breast carcinoma.
PIRP00003725	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00007700	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00004482	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00005319	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00000236	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00005272	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00000432	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00002023	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00005337	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00002638	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00002438	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00007897	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00003908	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00008101	21616063	piR-651	piR-hsa-1077	Breast carcinoma	EFO:0000305	upregulation	increased risk	breast cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Breast carcinoma.
PIRP00003612	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007614	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00004361	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00005196	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00000115	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00005138	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00000302	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00001876	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00005217	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00002536	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00002322	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007778	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00003785	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00007993	23992744	piR-932	piR-hsa-1519	Breast carcinoma	EFO:0000305	upregulation	poor progonosis	breast cancer cell lines	N/A	N/A	EMT signaling pathway	0.20	The piRNAs dysregulation associated with Breast carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Breast carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-932 may correlated with the poor progonosis of Breast carcinoma. Moreover, the molecular functions or physiological functions of piR-932 involving in the pathologies of Breast carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-932 is possibly correlated with the poor progonosis of Breast carcinoma.
PIRP00008305	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001134	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00008310	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003936	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003876	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005462	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00008112	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00004948	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001596	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007522	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005914	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000363	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001520	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002197	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003622	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003135	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005589	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00008014	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002518	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00004542	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00006786	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003765	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007633	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000855	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007984	26071182	piR-57125	piR-hsa-20266	Clear cell renal cell carcinomas	EFO:0000349	downregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007978	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002398	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005355	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007700	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005306	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003686	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000572	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005319	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001393	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000236	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005272	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002023	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005358	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007332	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00008285	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000185	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002638	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00006884	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000233	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00006625	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001227	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001282	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003827	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002022	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003908	26071182	piR-30924	piR-hsa-1077	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-30924 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001128	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003075	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00001191	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005816	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005828	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007429	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000888	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00006838	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003487	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000289	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007818	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002344	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00003494	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00004044	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005494	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005093	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00007590	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000852	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00004462	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00006480	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00008738	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00005701	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000422	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00002842	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00000818	26071182	piR-38756	piR-hsa-30978	Clear cell renal cell carcinomas	EFO:0000349	upregulation	poor progonosis	clear cell renal cell carcinomas patients	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Clear cell renal cell carcinomas was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Clear cell renal cell carcinomas was validated by RT-PCR. The validated results indicated that the upregulation of piR-38756 may correlated with the poor progonosis of Clear cell renal cell carcinomas.
PIRP00004101	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00005787	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00007978	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00001868	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00008067	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00008190	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00006373	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00008372	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00005319	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00006507	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00000236	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00005272	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00002023	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00000914	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00006665	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00005401	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00004070	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00007577	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00007623	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00002638	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00007082	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00003908	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00004228	21616063	piR-651	piR-hsa-1077	Colon carcinoma	EFO:1001950	upregulation	increased risk	colon cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colon carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colon carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Colon carcinoma.
PIRP00007163	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00004442	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00002288	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00001858	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00008066	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00008513	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00007126	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00008860	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00007932	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00004352	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00001387	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00008903	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00003433	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00004560	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00000261	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00000450	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00003177	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00008581	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00000270	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00003901	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00001927	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00003964	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00004242	30555542	piR-54265	piR-hsa-17444	Colorectal adenocarcinoma	EFO:0000365	upregulation	increased risk	colorectal adenocarcinoma	N/A	PIWIL2	STAT3 signaling pathway, cell proliferation, metastasis and chemoresistance	0.80	The piRNAs dysregulation associated with Colorectal adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-54265 may correlated with the increased risk of Colorectal adenocarcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-54265 involving in the pathologies of Colorectal adenocarcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-54265 dysregulation associated with the pathologies of Colorectal adenocarcinoma. Altogether, all above results suggested that the upregulation of piR-54265 is possibly correlated with the increased risk of Colorectal adenocarcinoma.
PIRP00000854	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00006031	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003184	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003313	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003502	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00001612	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00000452	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00002112	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00008375	29382334	piR-1245	piR-hsa-1963	Colorectal cancer	EFO:0005842	upregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	ATF3; BTG1; DUSP1; FAS,NFKBIA; UPP1; SESN2; TP53INP1; MDX1	Cell proliferation, cell death and apoptosis	0.40	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-1245 may correlated with the increased risk and poor progonosis of Colorectal cancer. Moreover, both molecular functions and physiological functions of piR-1245 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-1245 is possibly correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00008559	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00005604	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00001908	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00001839	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00004184	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003249	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00007090	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003499	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00000341	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00008091	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003654	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003522	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00003368	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00005799	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00002334	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00005857	29382334	piR-26525	piR-26525	Colorectal cancer	EFO:0005842	downregulation	increased risk and poor progonosis	colorectal cancer patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the downregulation of piR-26525 may correlated with the increased risk and poor progonosis of Colorectal cancer.
PIRP00007836	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00000900	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00003896	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00001021	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00001152	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00001325	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00007336	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00008522	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00002315	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00007281	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00004022	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00007477	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00004693	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00000010	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00005926	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00006257	28618124	piR-823	piR-hsa-1282	Colorectal cancer	EFO:0005842	upregulation	increased risk	colorectal cancer patients and colorectal cancer cell lines	N/A	HSF1	Cell proliferation, cell death and apoptosis	0.60	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk of Colorectal cancer. Moreover, both molecular functions, physiological functions and mechanisms of piR-823 involving in the pathologies of Colorectal cancer are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk of Colorectal cancer.
PIRP00000808	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00007706	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00007355	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00004473	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00004971	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00005260	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00004334	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00000723	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00006861	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00005302	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00008853	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00005770	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00005033	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00005779	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00007447	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00000345	25740697	piR-015551	piR-hsa-21517	Colorectal cancer	EFO:0005842	rs11776042	decreased risk	colorectal cancer 	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Colorectal cancer was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Colorectal cancer was validated by RT-PCR. The validated results indicated that the rs11776042 of piR-015551 may correlated with the decreased risk of Colorectal cancer.
PIRP00006169	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007133	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006632	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000297	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001705	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005448	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008125	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007275	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00009016	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001748	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007809	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005649	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007310	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008807	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000052	25779424	FR222326	FR222326	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR222326 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005387	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006261	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005763	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008591	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000881	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004660	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007297	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006467	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008245	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000863	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006999	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004822	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006432	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007971	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008329	25779424	FR157678	FR157678	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR157678 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001780	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002655	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002177	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005040	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006388	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001050	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003665	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002885	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004677	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006367	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003415	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001179	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002908	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004369	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004778	25779424	FR387750	FR387750	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR387750 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005694	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006676	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006094	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008907	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001225	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00004997	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007650	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006771	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008572	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001205	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007342	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005158	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006815	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008273	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008668	25779424	FR381169	FR381169	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR381169 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000403	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001370	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000784	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003664	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005065	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008757	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002338	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001498	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003343	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005042	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002057	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008880	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001519	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003023	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00003435	25779424	FR290353	FR290353	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR290353 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007129	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008074	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00007575	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001273	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002637	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006408	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00009048	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008200	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000910	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00002620	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008725	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00006528	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00008222	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00000617	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00001024	25779424	FR064000	FR064000	Gastric carcinoma	EFO:0000178	upregulation	poor progonosis	gastric cancer recurrence	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of FR064000 may correlated with the poor progonosis of Gastric carcinoma.
PIRP00005787	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00007978	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00001112	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00001868	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00006373	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00008372	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00002514	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00005319	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00000236	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00005272	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00002023	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00007257	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00002638	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00006664	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00003908	21616063	piR-651	piR-hsa-1077	Gastric carcinoma	EFO:0000178	upregulation	increased risk and poor progonosis	gastric cancer and  gastric cancer cell lines	N/A	N/A	Cell proliferation	0.40	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk and poor progonosis of Gastric carcinoma. Moreover, both molecular functions and physiological functions of piR-651 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the increased risk and poor progonosis of Gastric carcinoma.
PIRP00007836	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00000900	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00003141	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00003896	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00008353	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00001325	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00004536	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00007336	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00002315	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00007281	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00004022	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00000166	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00004693	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00008655	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00005926	22047710	piR-823	piR-hsa-1282	Gastric carcinoma	EFO:0000178	downregulation	increased risk	gastric cancer cells	N/A	N/A	Cell proliferation	-0.8	The piRNAs dysregulation associated with Gastric carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Gastric carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-823 may correlated with the increased risk of Gastric carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Gastric carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Gastric carcinoma. Altogether, all above results suggested that the downregulation of piR-823 is possibly correlated with the increased risk of Gastric carcinoma.
PIRP00001573	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00001697	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00003338	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00007490	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00004177	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00008625	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00006201	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00004765	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00002111	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00006490	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00002913	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00003386	27197292	piR-598	piR-hsa-1006	Glioma	EFO:0005543	rs147061479	increased risk	glioma cell	N/A	N/A	Cell proliferation	-0.4	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs147061479 of piR-598 may correlated with the increased risk of Glioma. Moreover, both molecular functions and physiological functions of piR-598 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs147061479 of piR-598 is possibly correlated with the increased risk of Glioma.
PIRP00006157	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00006259	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00007835	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00002863	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00008663	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00004145	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00001708	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00000134	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00006597	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00001946	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00007435	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00007870	27197292	piR-2799	piR-hsa-4045	Glioma	EFO:0005543	rs149336947	increased risk	glioma cell	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs149336947 of piR-2799 may correlated with the increased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-2799 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs149336947 of piR-2799 is possibly correlated with the increased risk of Glioma.
PIRP00001238	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00006828	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00007611	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00007325	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00002566	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00006986	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00006084	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00003885	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00004555	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00001449	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00004999	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00006944	27197292	piR-18913	piR-hsa-26213	Glioma	EFO:0005543	rs62435800	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs62435800 of piR-18913 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-18913 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs62435800 of piR-18913 is possibly correlated with the decreased risk of Glioma.
PIRP00005280	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00001837	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00002553	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00002250	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00006660	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00001994	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00001099	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00007902	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00008540	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00005479	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00009017	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00001886	27197292	piR-11714	piR-hsa-16119	Glioma	EFO:0005543	rs142742690	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs142742690 of piR-11714 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-11714 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs142742690 of piR-11714 is possibly correlated with the decreased risk of Glioma.
PIRP00003094	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00003222	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00004782	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00008831	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00005620	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00001100	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00007743	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00006183	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00003556	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00007962	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00004341	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00004831	27197292	piR-3266	piR-hsa-4668	Glioma	EFO:0005543	rs35712968	decreased risk	glioma cell	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Glioma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Glioma was validated by RT-PCR. The validated results indicated that the rs35712968 of piR-3266 may correlated with the decreased risk of Glioma. Moreover, the molecular functions or physiological functions of piR-3266 involving in the pathologies of Glioma are illustrated in cell lines in vitro. Altogether, all above results suggested that the rs35712968 of piR-3266 is possibly correlated with the decreased risk of Glioma.
PIRP00006624	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005535	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002251	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001040	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000421	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002756	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004692	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003213	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004268	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005743	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004216	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004005	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007769	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006030	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001357	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001144	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003877	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004667	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003592	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006879	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000231	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005594	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006273	27323410	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002975	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001880	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007694	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006520	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005861	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008151	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001029	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008606	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000666	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002182	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000542	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000339	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004093	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002468	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006778	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006563	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000268	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000992	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009040	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003262	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005672	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001950	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002685	27323410	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003053	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001956	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007745	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006601	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005925	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008218	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001107	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008675	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000731	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002260	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000616	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000413	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004169	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002537	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006858	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006658	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000343	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001083	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000053	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003330	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005753	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002037	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002783	27323410	piR-33044	piR-hsa-23210	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33044 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007249	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006137	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002862	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001723	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001131	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003370	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005376	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003888	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004976	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006437	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004855	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004639	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008336	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006720	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002077	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001767	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004558	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005293	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004271	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007569	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000920	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006199	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006949	27323410	piR-39307	piR-hsa-31511	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-39307 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007162	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006039	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002773	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001628	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001035	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003277	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005295	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003791	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004878	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006344	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004770	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004539	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008257	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006636	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001976	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001683	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004472	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005210	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004168	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007473	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000825	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006112	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006847	27323410	piR-36246	piR-hsa-28395	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36246 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005513	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004351	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001127	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008952	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008389	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001540	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003577	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002107	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003168	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004648	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003107	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002852	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006657	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004965	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000239	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000018	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002792	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003555	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002483	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005699	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008212	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004489	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005198	27323410	piR-61919	piR-hsa-26039	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-61919 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008930	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004618	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008661	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004937	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007861	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006673	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007301	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006300	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008081	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001264	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006244	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000461	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003014	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005204	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001934	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001319	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003660	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008799	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005303	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008424	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008843	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001101	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004955	27323410	piR-45029	piR-hsa-7238	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-45029 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006317	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005187	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001941	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000716	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000114	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002382	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004383	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002919	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003953	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005457	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003911	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003647	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007519	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005728	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001086	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000752	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003585	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004360	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003298	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006498	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008992	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005324	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005951	27323410	piR-34440	piR-hsa-26590	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-34440 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007185	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006066	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002798	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001664	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001065	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003297	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005327	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003823	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004910	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006376	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004789	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004556	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008276	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006671	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002011	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001700	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004508	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005234	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004193	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007500	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000849	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006134	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006875	27323410	piR-36716	piR-hsa-28850	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36716 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007101	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005998	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002719	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001571	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000975	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003231	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005255	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003741	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004836	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006299	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004713	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004504	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008215	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006579	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001926	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001625	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004438	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005164	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004125	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007399	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000778	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006057	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006805	27323410	piR-36715	piR-hsa-28849	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36715 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005896	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001500	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005603	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001815	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004801	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003525	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004191	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003157	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005036	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007299	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003092	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006482	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008892	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002106	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007929	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007371	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000565	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005731	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002205	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005330	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005798	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007089	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001779	27323410	piR-41794	piR-hsa-3961	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-41794 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007099	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005996	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002718	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001566	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000973	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003229	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005252	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003740	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004835	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006296	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004711	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004500	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008214	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006577	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001925	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001621	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004437	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005160	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004123	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007398	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000776	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006056	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006803	27323410	piR-36714	piR-hsa-28848	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36714 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007097	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005994	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002714	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001564	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000972	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003227	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005250	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003738	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004833	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006293	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004709	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004498	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008211	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006575	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001924	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001619	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004436	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005157	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004122	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007394	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000775	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006055	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006800	27323410	piR-36713	piR-hsa-28847	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36713 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007159	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006038	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002771	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001624	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001033	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003276	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005292	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003789	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004876	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006341	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004769	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004538	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008253	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006635	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001974	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001681	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004471	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005209	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004167	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007471	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000823	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006110	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006845	27323410	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002782	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001678	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007511	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006320	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005646	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007955	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000786	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008394	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000374	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001890	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000326	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000127	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003893	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002189	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006587	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006380	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000064	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000762	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008834	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003037	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005482	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001731	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002418	27323410	piR-37523	piR-hsa-29714	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37523 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002785	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001682	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007515	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006326	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005650	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007959	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000788	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008398	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000377	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001896	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000329	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000132	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003895	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002191	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006590	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006383	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000071	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000766	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008838	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003042	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005487	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001735	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002422	27323410	piR-37525	piR-hsa-29716	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37525 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002784	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001680	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007514	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006324	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005648	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007957	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000787	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008397	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000375	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001893	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000327	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000129	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003894	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002190	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006589	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006382	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000068	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000765	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008836	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003041	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005485	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001732	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002420	27323410	piR-37524	piR-hsa-29715	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-37524 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004552	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003423	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000143	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008033	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007524	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000580	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002606	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001135	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002212	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003683	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002164	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001885	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005677	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003965	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008354	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008090	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001812	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002589	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001494	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004780	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007296	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003539	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004198	27323410	piR-34736	piR-hsa-26872	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	EMT signaling pathway and cell apoptosis 	0.20	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Head and neck squamous cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34736 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma. Moreover, the molecular functions or physiological functions of piR-34736 involving in the pathologies of Head and neck squamous cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34736 is possibly correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001143	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000031	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005838	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004746	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004109	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006351	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008326	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006862	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007944	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000315	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007842	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007668	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002297	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000619	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005080	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004779	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007617	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008238	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007270	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001411	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003927	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000094	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000843	27323410	piR-36082	piR-hsa-28231	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36082 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000391	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008302	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005120	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003906	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003337	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005543	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007605	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006064	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007144	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008589	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007084	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006797	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001524	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008864	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004251	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004010	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006739	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007583	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006453	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000589	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003139	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008435	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000038	27323410	piR-34291	piR-hsa-26441	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34291 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003363	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002270	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008026	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006904	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006314	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008511	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001455	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009030	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001063	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002548	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000918	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000718	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004480	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002851	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007261	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006941	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000657	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001360	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000354	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003616	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006131	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002333	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003066	27323410	piR-36318	piR-hsa-28467	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008419	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004053	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008194	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004366	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007331	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006127	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006785	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005752	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007610	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000717	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005696	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000003	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002476	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004726	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001374	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000851	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003129	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008323	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004829	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007918	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008383	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000530	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004395	27323410	piR-43772	piR-hsa-5938	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43772 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008416	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004052	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008193	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004365	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007330	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006126	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006782	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005749	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007604	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000715	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005693	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009057	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002474	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004724	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001373	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000850	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003125	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008320	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004827	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007916	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008382	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000529	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004393	27323410	piR-43771	piR-hsa-5937	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43771 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008979	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007931	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004740	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003521	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002929	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005173	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007175	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005660	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006728	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008203	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006623	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006427	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001147	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008488	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003851	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003559	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006360	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007136	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006047	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000187	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002751	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008057	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008734	27323410	piR-54907	piR-hsa-18071	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54907 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000733	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006413	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007387	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007466	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001836	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005489	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006985	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004546	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008590	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006987	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006222	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009056	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008739	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004963	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002747	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004384	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005803	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008535	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004173	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005194	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004128	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006452	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006231	27323410	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003311	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002221	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007992	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006844	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006262	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008466	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001413	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008980	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000998	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002503	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000867	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000676	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004516	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002808	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007222	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006892	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000606	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001296	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000295	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003571	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006078	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002281	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003026	27323410	piR-35466	piR-hsa-27137	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35466 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003315	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002224	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007995	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006846	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006265	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008467	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001416	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008982	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001001	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002504	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000869	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000677	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004519	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002809	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007224	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006894	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000608	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001298	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000296	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003574	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006080	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002282	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003027	27323410	piR-35467	piR-hsa-27138	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35467 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003317	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002227	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007998	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006849	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006269	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008468	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001417	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008985	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001002	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002507	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000871	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000678	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004521	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002811	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007227	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006897	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000612	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001300	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000301	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003576	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006081	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002283	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003028	27323410	piR-35468	piR-hsa-27139	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35468 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001951	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000751	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006640	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005442	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004870	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007064	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009032	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007648	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008635	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001077	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008588	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008314	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003074	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001332	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005776	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005552	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008261	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009009	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007989	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002147	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004673	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000885	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001582	27323410	piR-62011	piR-hsa-26131	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-62011 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001081	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009015	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005758	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004645	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004031	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006260	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008260	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006770	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007869	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000241	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007755	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007603	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002223	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000535	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004993	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004691	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007544	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008168	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007205	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001309	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003859	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000020	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000761	27323410	piR-36074	piR-hsa-28223	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36074 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003396	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002290	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008047	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006928	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006347	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008532	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001477	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000002	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001092	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002562	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000944	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000739	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004567	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002872	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007292	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006978	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000680	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001390	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000372	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003633	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006154	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002356	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003086	27323410	piR-35469	piR-hsa-27140	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-35469 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002072	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000866	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006738	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005555	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004980	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007203	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000089	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007739	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008760	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001171	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008716	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008433	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003199	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001457	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005881	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005596	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008361	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000070	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008092	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002274	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004804	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001023	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001714	27323410	piR-34456	piR-hsa-26606	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003846	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002775	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008510	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007475	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006802	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008997	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001988	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000467	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001544	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003056	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001426	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001232	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004998	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003356	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007761	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007518	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001165	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001883	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000853	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004104	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006643	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002832	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003575	27323410	piR-33510	piR-hsa-22905	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-33510 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008069	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006992	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003691	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002499	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001907	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004186	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006133	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004672	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005710	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007226	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005659	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005478	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000106	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007563	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002849	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002599	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005349	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006111	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005073	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008316	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001720	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007048	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007744	27323410	piR-61298	piR-hsa-25447	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-61298 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006620	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005529	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002248	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001034	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000418	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002753	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004689	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003209	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004266	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005739	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004210	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004003	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007764	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006026	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001354	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001140	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003874	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004664	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003588	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006874	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000227	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005591	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006264	27323410	piR-49143	piR-hsa-11360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49143 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005135	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004011	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000702	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008653	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008073	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001219	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003261	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001770	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002845	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004307	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002717	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002516	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006240	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004612	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008964	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008702	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002455	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003159	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002154	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005395	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007910	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004068	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004860	27323410	piR-36040	piR-hsa-28189	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36040 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008357	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003999	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008086	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004303	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007268	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006061	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006694	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005688	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007562	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000664	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005640	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008921	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002429	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004574	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001303	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000730	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003069	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008209	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004700	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007865	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008265	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000472	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004333	27323410	piR-31355	piR-hsa-1580	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-31355 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005133	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004007	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000697	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008644	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008071	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001215	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003259	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001766	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002841	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004302	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002711	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002511	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006237	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004602	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008961	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008699	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002453	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003153	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002150	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005391	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007908	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004066	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004857	27323410	piR-36038	piR-hsa-28187	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36038 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005134	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004009	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000700	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008647	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008072	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001217	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003260	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001769	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002843	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004305	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002713	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002513	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006238	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004606	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008962	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008700	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002454	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003156	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002153	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005392	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007909	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004067	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004859	27323410	piR-36039	piR-hsa-28188	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36039 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005214	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004072	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000763	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008731	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008143	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001280	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003329	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001829	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002912	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004385	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002794	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002576	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006313	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004686	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00009044	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008777	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002521	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003233	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002236	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005461	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007970	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004148	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004941	27323410	piR-36041	piR-hsa-28190	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36041 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002172	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001074	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006833	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005715	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005156	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007380	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000252	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007900	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008906	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001327	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008810	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008605	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003387	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001656	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006050	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005760	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008533	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000164	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008248	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002437	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004974	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001130	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001881	27323410	piR-35284	piR-hsa-27493	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35284 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006622	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005534	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002249	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001038	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000419	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002755	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004690	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003210	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004267	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005740	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004213	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004004	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007767	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006028	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001355	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001141	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003875	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004666	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003591	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006877	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000228	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005593	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006268	27323410	piR-49144	piR-hsa-11361	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49144 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007152	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006033	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002768	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001616	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001028	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003273	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005285	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003783	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004874	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006333	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004762	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004535	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008250	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006630	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001968	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001673	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004468	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005203	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004161	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007453	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000817	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006106	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006842	27323410	piR-36241	piR-hsa-28390	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36241 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007487	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006328	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003044	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001911	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001231	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003546	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005484	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003984	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005169	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006529	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005047	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004839	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008520	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006903	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002187	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001959	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004774	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005464	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004463	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007715	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001062	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006402	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007161	27323410	piR-33534	piR-hsa-23670	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33534 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000937	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005638	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000639	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005933	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008859	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007734	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008299	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007370	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000035	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002341	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007316	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001514	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004043	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006214	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002977	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002404	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004741	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000758	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006319	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000395	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000821	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002148	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005950	27323410	piR-31531	piR-hsa-1742	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-31531 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002527	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001412	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007223	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006069	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005420	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007730	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000544	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008158	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000126	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001640	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000083	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008932	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003650	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001936	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006357	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006120	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008820	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000521	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008597	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002807	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005265	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001463	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002180	27323410	piR-33880	piR-hsa-24016	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33880 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008114	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007033	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003729	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002604	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002041	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004241	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006248	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004805	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005836	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007340	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005709	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005521	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000152	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007662	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002957	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002636	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005463	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006156	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005186	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008360	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001828	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007092	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007855	27323410	piR-35855	piR-hsa-28019	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35855 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002288	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001167	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006964	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005762	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005208	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007434	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000294	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007932	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008938	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001387	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008903	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008733	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003433	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001693	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006108	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005872	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008581	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000275	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008288	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002477	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005009	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001233	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001927	27323410	piR-54265	piR-hsa-17444	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-54265 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003517	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002416	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008175	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007067	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006469	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008672	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001629	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000124	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001204	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002691	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001108	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000875	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004644	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002996	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007460	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007112	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000807	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001512	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000505	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003766	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006287	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002479	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003241	27323410	piR-36338	piR-hsa-28487	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36338 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003236	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002129	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007915	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006754	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006189	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008384	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001314	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008901	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000904	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002421	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000780	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000588	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004424	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002702	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007123	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006809	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000518	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001241	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000219	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003493	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005993	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002195	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002940	27323410	piR-35221	piR-hsa-27124	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-35221 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002716	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008328	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000208	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000248	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003793	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007502	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008887	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006485	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001476	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008890	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008164	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001980	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001623	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006864	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004699	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006331	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007766	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001422	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006128	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007115	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006079	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008377	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008174	27323410	piR-30456	piR-hsa-624	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-30456 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003520	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002419	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008178	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007071	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006470	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008674	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001633	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000128	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001206	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002696	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001110	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000877	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004647	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002997	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007470	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007114	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000810	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001515	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000510	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003769	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006292	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002482	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003243	27323410	piR-36340	piR-hsa-28489	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36340 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005955	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004905	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001570	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000433	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008835	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002105	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004023	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002555	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003685	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005113	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003573	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003392	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007108	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005466	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000703	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000470	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003316	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003992	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003006	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006230	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008667	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004973	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005679	27323410	piR-33856	piR-hsa-23992	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33856 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002133	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006817	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001900	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007125	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000978	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008852	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000462	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008493	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001221	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003505	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008445	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002715	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005267	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007426	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004146	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003570	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005874	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002050	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007561	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001580	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002044	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003341	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007164	27323410	piR-43996	piR-hsa-6147	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43996 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002131	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006814	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001899	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007122	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000974	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008851	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000460	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008490	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001218	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003504	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008444	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002712	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005264	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007424	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004144	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003568	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005873	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002049	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007559	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001578	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002043	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003336	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007160	27323410	piR-43995	piR-hsa-6146	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43995 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002128	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006806	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001897	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007119	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000970	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008844	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000458	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008485	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001213	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003498	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008440	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002701	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005254	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007420	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004138	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003565	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005868	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002048	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007553	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001572	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002038	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003328	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007155	27323410	piR-43992	piR-hsa-6143	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-43992 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001659	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007319	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008230	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008279	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002752	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006391	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007885	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005446	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000410	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007888	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007121	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000883	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000540	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005827	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003623	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005299	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006700	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000358	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005097	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006044	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005060	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007374	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007146	27323410	piR-30840	piR-hsa-993	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30840 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008305	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007253	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003936	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002765	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002162	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004379	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006398	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004948	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005954	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007522	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005914	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005719	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000363	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007758	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003082	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002875	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005589	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006375	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005325	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008501	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001979	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007321	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007984	27323410	piR-57125	piR-hsa-20266	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57125 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007095	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005989	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002710	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001562	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000969	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003224	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005248	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003736	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004830	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006291	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004707	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004496	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008210	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006573	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001923	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001618	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004431	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005155	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004119	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007393	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000774	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006054	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006799	27323410	piR-36712	piR-hsa-28846	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36712 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001275	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000171	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005965	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004815	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004185	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006479	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008404	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006940	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008012	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000396	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007969	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007783	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002436	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000689	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005150	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004929	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007670	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008374	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007450	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001543	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003996	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000232	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000919	27323410	piR-60238	piR-hsa-24360	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-60238 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007091	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005988	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00002705	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001561	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000968	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003221	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005247	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00003735	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004828	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006289	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004705	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004494	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00008208	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006570	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001922	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00001615	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004429	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00005153	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00004116	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00007391	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000772	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006052	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00006796	27323410	piR-36711	piR-hsa-28845	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-36711 may correlated with the increased risk of Head and neck squamous cell carcinoma.
PIRP00000733	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006413	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007387	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007466	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001836	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005489	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006985	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004546	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008590	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006987	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006222	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00009056	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008739	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004963	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002747	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004384	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005803	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008535	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004173	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005194	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004128	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006452	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006231	28109471	piR-30229	piR-hsa-426	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-30229 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006624	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005535	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002251	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001040	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000421	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002756	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004692	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003213	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004268	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005743	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004216	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004005	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007769	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006030	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001357	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001144	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003877	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004667	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003592	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006879	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000231	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005594	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006273	28109471	piR-49145	piR-hsa-11362	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-49145 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002975	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001880	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007694	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006520	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005861	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008151	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001029	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008606	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000666	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002182	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000542	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000339	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004093	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002468	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006778	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006563	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000268	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000992	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00009040	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003262	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005672	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001950	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002685	28109471	piR-33043	piR-hsa-23209	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-33043 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007159	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006038	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002771	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001624	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001033	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003276	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005292	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003789	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004876	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006341	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004769	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004538	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008253	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006635	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001974	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001681	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004471	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00005209	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004167	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007471	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000823	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006110	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006845	28109471	piR-36245	piR-hsa-28394	Head and neck squamous cell carcinoma	EFO:0000181	upregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36245 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003402	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002296	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008128	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006930	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006356	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008543	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001485	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000007	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001095	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002569	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001046	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000743	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00004579	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002882	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00007305	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006984	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000684	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00001460	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00000381	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003644	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00006162	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00002425	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00003089	28109471	NONHSAT067200	NONHSAT067200	Head and neck squamous cell carcinoma	EFO:0000181	downregulation	increased risk and poor progonosis	head and neck squamous cell carcinoma	tobacco	N/A	N/A	-0.05	The piRNAs dysregulation associated with Head and neck squamous cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of NONHSAT067200 may correlated with the increased risk and poor progonosis of Head and neck squamous cell carcinoma.
PIRP00008142	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004147	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002680	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004103	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005357	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008601	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005726	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000409	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006065	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008280	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006855	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006572	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001823	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005396	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007956	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004758	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002797	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004034	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008220	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001208	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006370	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007052	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008388	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005526	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002621	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007118	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003189	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007308	23376363	piR-Hep1	piR-hsa-8438265	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	hepatocellular carcinoma patients and  hepatocellular lines	N/A	Akt	Akt signaling pathway	0.40	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Hepatocellular carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-Hep1 may correlated with the increased risk of Hepatocellular carcinoma. Moreover, both molecular functions and physiological functions of piR-Hep1 involving in the pathologies of Hepatocellular carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-Hep1 is possibly correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00006539	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00000414	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00002789	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00004796	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00005580	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00002411	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00003429	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00004401	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00004446	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00001719	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00005417	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Renal carcinoma	EFO:0002890	upregulation	increased risk	kidney cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Renal carcinoma.
PIRP00004487	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00004320	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00003541	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00008181	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00001507	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00000527	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00004810	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00000435	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00005793	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00005528	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00008094	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00001272	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00007857	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00008301	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00008531	26205624	piR_011186	piR-hsa-15404	Leukemia	EFO:0000565	upregulation	increased risk	leukemia cell line U937	N/A	CDKN2B; DNMT1; Suv39H1;  EZH2	Cell cycle  and cell apoptosis	0.40	The piRNAs dysregulation associated with Leukemia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Leukemia was validated by RT-PCR. The validated results indicated that the upregulation of piR_011186 may correlated with the increased risk of Leukemia. Moreover, both molecular functions and physiological functions of piR_011186 involving in the pathologies of Leukemia are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR_011186 is possibly correlated with the increased risk of Leukemia.
PIRP00006493	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008305	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005070	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005235	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003936	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006670	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004948	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005386	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007522	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005914	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008076	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000363	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001520	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001595	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001249	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005589	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004925	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005811	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005647	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000855	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007984	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004787	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006226	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000728	28460486	piR-57125	piR-hsa-20266	Lung adenocarcinoma	EFO:0000571	downregulation	poor progonosis	lung adenocarcinoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-57125 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007705	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000391	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006195	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006374	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005120	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007838	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006064	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006524	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008589	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007084	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000142	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001524	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002697	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002788	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002428	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006739	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006042	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006969	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006808	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002055	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000038	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005911	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007440	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001915	27829231	DQ596225	piR-hsa-26441	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596225 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003948	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005771	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002490	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002631	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001365	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004081	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002369	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002835	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004931	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003393	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005533	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006896	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008053	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008116	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007795	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003040	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002351	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003267	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003097	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007448	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005424	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002218	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003679	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007289	27829231	DQ596306	piR-hsa-26522	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596306 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003952	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005778	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002493	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002633	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001372	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004086	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002374	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002840	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004940	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003399	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005538	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006905	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008056	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008120	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007799	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003047	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002354	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003272	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003102	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007452	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005430	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002226	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003682	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007295	27829231	DQ596309	piR-hsa-26525	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596309 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004355	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00006165	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002891	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003051	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00001784	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004493	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002763	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003226	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005323	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003752	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005906	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007318	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008431	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008495	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00008154	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003445	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002732	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003634	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00003501	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007814	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00005817	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00002592	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00004059	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00007693	27829231	DQ596354	piR-hsa-26570	Lung adenocarcinoma	EFO:0000571	upregulation	poor progonosis	lung adenocarcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung adenocarcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung adenocarcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Lung adenocarcinoma.
PIRP00000049	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00001286	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00002789	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00007300	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00000782	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00004637	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00000373	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00002690	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00003636	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00002979	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00001783	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00000497	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00006967	29382334	piR-1245	piR-hsa-1963	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and cell lines	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Lung carcinoma.
PIRP00004912	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006629	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003572	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002255	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005049	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003287	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003671	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005829	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004218	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006448	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00007845	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008676	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003946	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003275	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004164	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004018	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006352	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003061	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004611	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008173	28423657	piR-34871	piR-hsa-27007	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-34871 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-34871 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-34871 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001665	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003425	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000310	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008077	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001722	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00009010	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000420	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002532	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000976	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003161	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004533	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005476	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000701	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008989	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000846	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000767	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003058	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008862	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001352	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004986	28423657	piR-52200	piR-hsa-15399	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	0.40	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-52200 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-52200 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-52200 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003657	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005412	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002362	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001004	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003803	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002065	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002461	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004603	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003000	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005263	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006604	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00007543	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002748	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002052	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002954	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002823	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005149	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001827	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003409	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006976	28423657	piR-35127	piR-hsa-27351	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-35127 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-35127 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-35127 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002551	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005549	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003774	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005274	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000658	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002870	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003303	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006910	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002826	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00007107	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00008620	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002898	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000190	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005213	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006037	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005400	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001398	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004255	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002936	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000336	28423657	piR-46545	piR-hsa-8674	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer patients and lung cancer cell lines	N/A	AMPK	AMPK signaling pathway	-0.4	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-46545 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions and physiological functions of piR-46545 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-46545 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004995	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00007978	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00006206	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00007700	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00003099	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00005319	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00005714	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00000236	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00005272	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00000432	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00002023	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00005337	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00002638	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00007653	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00008516	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00007897	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00003908	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00006692	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00005440	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00002815	21616063	piR-651	piR-hsa-1077	Lung carcinoma	EFO:0001071	upregulation	increased risk	lung cancer tissues	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the increased risk of Lung carcinoma.
PIRP00002687	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000365	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001013	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00003036	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006980	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001871	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000699	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004223	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002952	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00000224	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00007576	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002948	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00007303	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00001814	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006309	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002558	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00006236	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00009004	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00005703	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00002591	26408181	piR-55490	piR-hsa-9	Lung carcinoma	EFO:0001071	downregulation	increased risk	lung cancer cells	N/A	mTOR	Akt/mTOR signaling pathway	-0.8	The piRNAs dysregulation associated with Lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-55490 may correlated with the increased risk of Lung carcinoma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-55490 involving in the pathologies of Lung carcinoma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-55490 dysregulation associated with the pathologies of Lung carcinoma. Altogether, all above results suggested that the downregulation of piR-55490 is possibly correlated with the increased risk of Lung carcinoma.
PIRP00004355	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00006165	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003051	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00001784	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00000559	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00004493	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00002763	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003226	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003811	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00005323	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003752	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00005906	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00007318	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00005586	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00000893	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00001838	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00008154	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00000600	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003445	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00002732	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003634	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00004190	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003132	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00006372	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00008846	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00003501	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00005168	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00005817	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00002592	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00004059	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00007693	27829231	DQ596354	piR-hsa-26570	Squamous cell lung carcinoma	EFO:0000708	upregulation	poor progonosis	lung squamous cell carcinoma samples	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Squamous cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Squamous cell lung carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of DQ596354 may correlated with the poor progonosis of Squamous cell lung carcinoma.
PIRP00008015	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00000307	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00000857	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00000900	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005884	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00004240	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00003242	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00008527	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005525	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00001825	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00003595	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00000729	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00007336	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00007281	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005126	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00002307	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005277	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005046	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00004693	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00006734	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00007094	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00001197	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00000352	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00004152	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00005926	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00004821	24732595	piR-823	piR-hsa-1282	Multiple myeloma	EFO:0001378	upregulation	increased risk and poor progonosis	multiple myeloma patients and multiple myeloma cell lines	N/A	DNMT3A and 3B	Cell proliferation, cell apoptosis, cell cycle and angiogenesis	0.80	The piRNAs dysregulation associated with Multiple myeloma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Multiple myeloma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Multiple myeloma. Moreover, both molecular functions, physiological functions and/or mechanisms of piR-823 involving in the pathologies of Multiple myeloma are illustrated in cell lines in vitro. Furthermore, the animal model experiments in vivo (eg. xenograft, transgenic) also demonstrated and supported the piR-823 dysregulation associated with the pathologies of Multiple myeloma. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Multiple myeloma.
PIRP00007829	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00008487	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00004735	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00003792	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00008181	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00003544	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00008840	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00005089	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00005369	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007946	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00003121	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00002635	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007056	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00004810	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007690	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00006794	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00005528	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00002442	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007195	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00003115	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00006430	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00005930	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007857	29516567	piR-52205	piR-hsa-15404	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52205 may correlated with the increased risk of Neuroblastoma.
PIRP00007830	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00008489	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00004736	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00003797	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00008184	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00003545	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00008841	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00005091	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00005370	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00007948	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00003122	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00002640	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00007057	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00004811	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00007691	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00006795	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00005532	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00002444	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00007197	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00003117	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00006431	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00005931	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00007859	29516567	piR-52206	piR-hsa-15405	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-52206 may correlated with the increased risk of Neuroblastoma.
PIRP00006841	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00007620	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00003830	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00002861	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00007258	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00002585	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00007927	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00004179	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00004479	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00007001	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00002262	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00001778	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00006105	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00003898	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00006707	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00005919	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00004570	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00001462	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00006298	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00002253	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00005477	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00005014	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00006972	29516567	piR-57816	piR-hsa-21000	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-57816 may correlated with the increased risk of Neuroblastoma.
PIRP00007419	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00008084	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00004354	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00003395	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00007790	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00003112	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00008428	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00004745	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00005028	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00007581	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00002787	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00002245	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00006639	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00004435	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00007248	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00006460	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00005116	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00002035	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00006741	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00002681	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00005987	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00005522	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00007558	29516567	piR-38581	piR-hsa-30715	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-38581 may correlated with the increased risk of Neuroblastoma.
PIRP00005644	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00006379	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00002617	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00001653	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00006123	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00001369	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00006721	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00002992	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00003292	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00005797	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00001044	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00000552	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00004947	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00002689	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00005510	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00004768	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00003405	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00000250	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00005112	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00001039	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00004273	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00003802	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00005767	29516567	piR-32512	piR-hsa-12623	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32512 may correlated with the increased risk of Neuroblastoma.
PIRP00007843	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00008506	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00004819	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00003813	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00008266	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00003557	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00008855	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00005182	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00005455	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00007965	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00003219	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00002760	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00007075	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00004890	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00007702	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00006887	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00005548	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00002460	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00007274	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00003212	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00006443	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00005945	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00007936	29516567	piR-32287	piR-hsa-12399	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32287 may correlated with the increased risk of Neuroblastoma.
PIRP00000815	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00001528	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00006873	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00005895	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00001223	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00005633	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00001913	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00007200	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00007600	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00000960	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00005334	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00004793	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00000067	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00006958	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00000675	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00008943	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00007675	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00004545	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00000177	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00005253	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00008508	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00008044	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00000933	29516567	piR-36095	piR-hsa-28244	Neuroblastoma	EFO:0000621	upregulation	increased risk	neuroblastoma	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Neuroblastoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36095 may correlated with the increased risk of Neuroblastoma.
PIRP00006973	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00004676	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00000865	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00005328	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00007322	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00002186	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00006212	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00005019	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00008473	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00007242	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00004595	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00002802	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00007239	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00002481	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00006089	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00001488	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00006823	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00001424	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00004314	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00000884	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00006852	26095918	piR-L-163	piR-L-163	Non-small cell lung carcinoma	EFO:0003060	downregulation	increased risk and poor progonosis	non-small cell lung cancer (NSCLC) cell lines	N/A	p-ERM	Cell cycle  and cell migration and cell invasion	-0.6	The piRNAs dysregulation associated with Non-small cell lung carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Non-small cell lung carcinoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-L-163 may correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma. Moreover, both molecular functions, physiological functions and mechanisms of piR-L-163 involving in the pathologies of Non-small cell lung carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-L-163 is possibly correlated with the increased risk and poor progonosis of Non-small cell lung carcinoma.
PIRP00004154	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008202	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00002085	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00005999	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008928	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008613	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00004846	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00004503	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006511	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00002346	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00005568	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008099	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006565	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00001043	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00002119	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006311	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000571	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008684	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00003410	25910082	piR-017061	piR-hsa-23822	Pancreatic carcinoma	EFO:0002618	downregulation	increased risk	pancreatic cancer	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-017061 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000882	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00007278	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00005787	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00004264	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00007978	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00001868	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00006373	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00004514	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00008372	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00000828	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00005319	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00000236	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00005272	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00002023	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00000824	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00002638	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00008633	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00003908	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00005310	27414029	piR-651	piR-hsa-1077	Pancreatic carcinoma	EFO:0002618	upregulation	decreased risk	prostate cancer cell lines	hormone treatment	N/A	Cell proliferation and EMT signaling pathway	-0.2	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-651 may correlated with the decreased risk of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-651 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-651 is possibly correlated with the decreased risk of Pancreatic carcinoma.
PIRP00002939	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00000184	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00007836	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00006285	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00000900	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00003896	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00008353	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00006504	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00001325	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00002897	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00007336	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00002315	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00007281	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00004022	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00002895	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00004693	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00001598	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00005926	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00007328	27414029	piR-823	piR-hsa-1282	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk and poor progonosis	prostate cancer cell lines	N/A	mTOR	Cell proliferation and EMT signaling pathway	0.20	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Pancreatic carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-823 may correlated with the increased risk and poor progonosis of Pancreatic carcinoma. Moreover, the molecular functions or physiological functions of piR-823 involving in the pathologies of Pancreatic carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-823 is possibly correlated with the increased risk and poor progonosis of Pancreatic carcinoma.
PIRP00005104	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00002373	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000854	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008410	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006031	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00001439	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008642	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00003502	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00005051	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00004448	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000298	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006171	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00005050	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00003745	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000348	29382334	piR-1245	piR-hsa-1963	Pancreatic carcinoma	EFO:0002618	upregulation	increased risk	prostate cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Pancreatic carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Pancreatic carcinoma.
PIRP00000900	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004417	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007405	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000604	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002612	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007336	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003461	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002315	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007281	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004022	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007409	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000230	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001248	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002264	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004693	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008876	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002312	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008621	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003281	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004021	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005926	27919963	piR-823	piR-hsa-1282	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	patientss with Renal Cell Carcinoma	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-823 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006172	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008037	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006182	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001789	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005946	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002772	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008432	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005332	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003762	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007327	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008439	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000009	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001378	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000949	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003455	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005851	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000321	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002397	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004659	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007822	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005830	25998508	piR-32051	piR-hsa-12178	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-32051 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-32051 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-32051 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008600	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001480	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008682	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004235	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008391	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005236	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001906	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007760	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006217	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000660	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001912	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002489	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003910	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003443	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005938	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008284	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002820	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004866	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007104	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001235	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008256	25998508	piR-39894	piR-hsa-32052	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-39894 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-39894 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-39894 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006768	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001201	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004163	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006557	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008542	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004098	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000207	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008156	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004051	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000797	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004250	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006200	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007143	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008108	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001459	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005705	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008221	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005517	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000039	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000796	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002757	25998508	piR-43607	piR-hsa-5773	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.20	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Renal cell carcinoma was validated by RT-PCR. The validated results indicated that the upregulation of piR-43607 may correlated with the increased risk and poor progonosis of Renal cell carcinoma. Moreover, the molecular functions or physiological functions of piR-43607 involving in the pathologies of Renal cell carcinoma are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of piR-43607 is possibly correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003363	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005329	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003450	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008026	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003146	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009030	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005682	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002548	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000918	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004480	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005692	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006275	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007737	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007241	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000657	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003035	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006681	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008609	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001816	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005076	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003066	25998508	piR-36318	piR-hsa-28467	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-36318 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002311	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004162	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002318	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006979	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002101	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007947	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004565	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001407	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008911	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003447	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004578	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005249	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006578	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006163	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008599	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001985	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005550	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007632	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000740	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003913	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001948	25998508	piR-32105	piR-hsa-12232	Renal cell carcinoma	EFO:0000681	upregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-32105 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006556	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000962	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003935	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006346	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008308	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003881	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009038	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007943	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003839	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000575	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004000	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005959	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006889	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007899	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001236	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005490	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008006	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005320	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008865	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000574	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002515	25998508	piR-4018	piR-hsa-5748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-4018 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000757	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002761	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000840	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005554	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000634	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006497	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003150	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009023	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007529	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002014	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003164	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003796	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005189	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004764	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007214	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000517	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004106	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006147	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008392	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002496	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000482	25998508	piR-58594	piR-hsa-21746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58594 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000760	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002762	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000842	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005556	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000638	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006499	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003152	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009024	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007530	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002016	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003166	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003798	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005192	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004767	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007217	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000520	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004108	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006151	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008393	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002497	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000485	25998508	piR-58595	piR-hsa-21747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-58595 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008093	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000879	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008100	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003709	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007905	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004698	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001359	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007244	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005681	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000131	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001289	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001966	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003421	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002916	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005371	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007811	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002295	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004319	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006567	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000637	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007763	25998508	piR-54403	piR-hsa-17582	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54403 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007550	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000330	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007625	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003181	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007378	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004131	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000737	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006691	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005181	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008669	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000742	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001402	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002793	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002368	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004838	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007255	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001738	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003764	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006024	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000082	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007231	25998508	piR-57849	piR-hsa-21033	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-57849 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002724	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004598	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002734	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007465	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002517	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008345	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005025	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001841	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000281	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003850	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005035	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005635	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007013	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006584	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009008	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002408	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005957	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008005	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001180	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004344	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002384	25998508	piR-32635	piR-hsa-12746	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32635 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002379	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005843	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008792	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002073	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004040	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008735	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004895	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003722	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008680	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005468	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008794	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001701	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002684	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003676	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006116	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001268	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003719	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000995	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004729	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005467	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007411	25998508	piR-45808	piR-hsa-7955	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45808 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002381	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005845	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008793	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002076	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004042	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008737	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004897	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003723	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008681	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005471	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008796	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001704	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002686	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003677	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006118	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001269	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003720	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000997	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004731	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005470	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007413	25998508	piR-45809	piR-hsa-7956	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-45809 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007704	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000526	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007773	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003302	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007537	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004332	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000934	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006860	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005300	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008850	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000941	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001508	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002971	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002550	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005031	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007498	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001932	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003949	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006221	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000265	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007444	25998508	piR-32986	piR-hsa-13197	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32986 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002726	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004601	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002736	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007469	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002520	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008346	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005026	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001844	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000282	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003852	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005037	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005637	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007014	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006586	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009011	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002410	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005958	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008008	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001181	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004347	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002387	25998508	piR-32636	piR-hsa-12747	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32636 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007703	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000524	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007771	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003300	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007535	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004331	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000932	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006857	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005298	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008849	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000939	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001506	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002969	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002549	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005030	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007495	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001931	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003947	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006220	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000264	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007439	25998508	piR-32985	piR-hsa-13196	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32985 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002729	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004605	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002740	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007472	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002523	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008347	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005027	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001845	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000283	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003855	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005038	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005639	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007016	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006588	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009013	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002412	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005961	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008010	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001182	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004350	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002388	25998508	piR-32637	piR-hsa-12748	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-32637 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000478	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002395	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000484	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005224	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000260	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006161	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002871	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008690	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007199	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001636	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002814	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003466	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004896	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004382	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006826	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000158	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003754	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005794	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008049	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002144	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000123	25998508	piR-54542	piR-hsa-17720	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54542 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003976	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005862	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003983	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008660	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003775	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000550	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006355	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003120	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001577	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005152	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006279	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006923	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008331	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007874	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001242	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003673	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007260	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000176	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002475	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005613	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003641	25998508	piR-54436	piR-hsa-17615	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-54436 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003994	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005942	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004071	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008670	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003801	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000568	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006366	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003142	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001590	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005172	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006381	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006931	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008342	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007893	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001302	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003690	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007273	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000189	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002492	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005691	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003718	25998508	piR-64616	piR-rno-50934	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-64616 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002644	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006139	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000006	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002434	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004428	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00009000	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005201	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004017	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008942	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005755	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000073	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002075	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002991	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003960	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006415	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001558	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004076	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001350	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005018	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005754	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007698	25998508	piR-43147	piR-hsa-5341	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-43147 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006241	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008118	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006254	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001859	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00006027	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002846	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008503	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005382	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003844	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007415	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00008509	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000078	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001448	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00001047	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00003519	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005917	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00000401	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00002466	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00004757	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007887	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00005885	25998508	piR-34434	piR-hsa-26584	Renal cell carcinoma	EFO:0000681	downregulation	increased risk and poor progonosis	renal cell carcinoma 	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Renal cell carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of piR-34434 may correlated with the increased risk and poor progonosis of Renal cell carcinoma.
PIRP00007193	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00000640	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00000986	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00004014	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00002427	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00004981	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00008646	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003903	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003920	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00000938	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00000469	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005970	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00002118	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00000948	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005924	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00002693	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00002431	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005982	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00008096	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003980	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003372	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005497	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005309	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003254	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00001406	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00001947	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00006634	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003081	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005516	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00008857	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00004624	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00005964	26265322	piR-004172	piR-hsa-5963	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Seminoma.
PIRP00003716	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006283	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006633	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00000555	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00007980	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00001425	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00005262	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00000431	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00000380	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006496	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006049	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002544	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00007750	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006592	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002498	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00008304	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00007981	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002484	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00004586	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00000451	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00008927	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002061	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00001826	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00008828	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00006977	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00007566	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00003110	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00008615	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002019	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00005456	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00001104	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00002541	26265322	piR-006113	piR-hsa-8632	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Seminoma.
PIRP00000017	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008259	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00002459	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00005656	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001008	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007762	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001726	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001563	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001652	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007247	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008409	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007417	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00004063	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00000822	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008366	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00002869	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007377	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008719	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00000309	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007898	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008046	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00005375	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007384	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00007513	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001497	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00000173	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00008824	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00006697	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00003880	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00003462	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00001351	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00005230	26265322	piR-007509	piR-hsa-10476	Seminoma	EFO:0003101	downregulation	increased risk	seminoma	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Seminoma was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Seminoma was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Seminoma.
PIRP00005122	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003324	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007671	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000058	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002791	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005271	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003826	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004324	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000878	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006821	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005333	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006365	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004748	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006798	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002473	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000455	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000769	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005013	23112866	DQ601291	piR-hsa-31561	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601291 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007523	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004675	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000848	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008545	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003412	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003465	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001279	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000150	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007849	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008134	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002988	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007586	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007314	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004326	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002415	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004566	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008327	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000907	23112866	DQ591415	piR-hsa-32	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ591415 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003364	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001534	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005860	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007446	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001003	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003492	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002084	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002560	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008205	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005096	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003552	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004610	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002963	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005082	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000691	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007824	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008110	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003258	23112866	DQ601609	piR-hsa-31849	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005567	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003693	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008083	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000446	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003172	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005619	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004202	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004809	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001336	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007238	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005675	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006801	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005207	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007230	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002874	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000845	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001252	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00005399	23112866	DQ589977	piR-hsa-20230	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008920	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007194	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00002432	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00003942	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006654	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000011	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00007664	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008171	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004803	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001611	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000004	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001142	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008562	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00001511	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00006343	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004276	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00004682	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00008827	23112866	DQ598918	piR-hsa-29218	Sertoli cell-only syndrome	EFO:1001422	downregulation	increased risk	sertoli cell-only syndrome and spermatogenic failure patients	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Sertoli cell-only syndrome was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Sertoli cell-only syndrome was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Sertoli cell-only syndrome.
PIRP00000854	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00003068	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00003502	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00006685	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00000357	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00002353	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00006811	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00008075	29382334	piR-1245	piR-hsa-1963	Stomach cancer	EFO:0003897	upregulation	increased risk	stomach cancer patients	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Stomach cancer was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of piR-1245 may correlated with the increased risk of Stomach cancer.
PIRP00006438	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00002432	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00008068	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00004803	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00008803	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00000874	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00002094	24247010	DQ598918	piR-hsa-29218	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ598918 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ598918 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ598918 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00002959	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00008083	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00004683	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00001336	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00005356	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00006553	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00007751	24247010	DQ589977	piR-hsa-20230	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ589977 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ589977 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ589977 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00000779	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00005860	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00002533	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00008205	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00003208	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00004349	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00005595	24247010	DQ601609	piR-hsa-31849	Testicular neoplasm	EFO:0004281	downregulation	increased risk	primary testicular tumors	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Testicular neoplasm was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular neoplasm was validated by RT-PCR. The validated results indicated that the downregulation of DQ601609 may correlated with the increased risk of Testicular neoplasm. Moreover, the molecular functions or physiological functions of DQ601609 involving in the pathologies of Testicular neoplasm are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of DQ601609 is possibly correlated with the increased risk of Testicular neoplasm.
PIRP00000640	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004014	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00002427	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004981	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008646	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003903	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000938	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005970	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00002118	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008096	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003980	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003372	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005309	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003254	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001947	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00006634	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003081	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008857	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004624	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005964	26265322	piR-004172	piR-hsa-5963	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-004172 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00006283	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000555	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007980	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001425	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005262	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000431	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00006496	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00002544	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007750	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004586	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000451	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008927	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001826	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008828	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007566	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003110	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008615	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005456	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001104	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00002541	26265322	piR-006113	piR-hsa-8632	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-006113 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008259	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005656	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001008	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007762	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001726	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001563	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007247	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007417	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004063	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000309	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007898	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008046	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007384	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00007513	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00000173	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00008824	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00006697	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00003462	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00001351	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00005230	26265322	piR-007509	piR-hsa-10476	Testicular germ cell tumor	EFO:1000566	downregulation	increased risk	testicular germ cell tumors	N/A	N/A	N/A	-0.1	The piRNAs dysregulation associated with Testicular germ cell tumor was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Testicular germ cell tumor was validated by RT-PCR. The validated results indicated that the downregulation of piR-007509 may correlated with the increased risk of Testicular germ cell tumor.
PIRP00004039	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00001042	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00008373	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00003053	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00004388	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00007307	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00004491	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00003966	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00005850	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00004197	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00002115	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00001194	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00001811	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00005909	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00001420	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00003432	27893851	DQ592932	piR-hsa-23210	Rheumatoid arthritis	EFO:0000685	upregulation	decreased risk	rheumatoid arthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Rheumatoid arthritis was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Rheumatoid arthritis was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Rheumatoid arthritis. Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Rheumatoid arthritis are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Rheumatoid arthritis.
PIRP00004039	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00003053	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00000088	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00008412	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00004388	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00007307	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00004491	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00003966	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00004197	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00002115	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00001194	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00003432	27893851	DQ592932	piR-hsa-23210	Osteoarthritis 	EFO:0002506	upregulation	decreased risk	osteoarthritis patients	N/A	N/A	LPS and TNF¦Á induced inflammatory	-0.2	The piRNAs dysregulation associated with Osteoarthritis  was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Osteoarthritis  was validated by RT-PCR. The validated results indicated that the upregulation of DQ592932 may correlated with the decreased risk of Osteoarthritis . Moreover, the molecular functions or physiological functions of DQ592932 involving in the pathologies of Osteoarthritis  are illustrated in cell lines in vitro. Altogether, all above results suggested that the upregulation of DQ592932 is possibly correlated with the decreased risk of Osteoarthritis .
PIRP00005680	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00005879	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00004893	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00007774	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00002056	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00007619	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00003215	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00001073	27068805	piR-30198	piR-hsa-395	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-30198 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-30198 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-30198 is possibly correlated with the increased risk of Azoospermia.
PIRP00001329	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00004064	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00000267	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00002829	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00000245	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00005984	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00004640	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00002394	27068805	piR-31068	piR-hsa-1207	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31068 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31068 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31068 is possibly correlated with the increased risk of Azoospermia.
PIRP00006345	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00009020	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00005314	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00007813	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00005281	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00001905	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00000504	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00007397	27068805	piR-31925	piR-hsa-2107	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-31925 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-31925 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-31925 is possibly correlated with the increased risk of Azoospermia.
PIRP00000398	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00003151	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00008416	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00001875	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00008395	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00005166	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00003760	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00001433	27068805	piR-43771	piR-hsa-5937	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43771 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43771 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43771 is possibly correlated with the increased risk of Azoospermia.
PIRP00000400	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00003158	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00008422	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00001879	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00008399	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00005170	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00003763	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00001436	27068805	piR-43773	piR-hsa-5939	Azoospermia	EFO:0000279	downregulation	increased risk	seminal plasma of infertile patients	N/A	N/A	N/A	-0.2	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of piR-43773 may correlated with the increased risk of Azoospermia. Moreover, the molecular functions or physiological functions of piR-43773 involving in the pathologies of Azoospermia are illustrated in cell lines in vitro. Altogether, all above results suggested that the downregulation of piR-43773 is possibly correlated with the increased risk of Azoospermia.
PIRP00004834	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00003018	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00007356	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00000587	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00006517	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00005032	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00004423	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00002185	29460056	DQ598679	piR-hsa-28879	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598679 may correlated with the increased risk of Azoospermia.
PIRP00008994	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00002674	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00007987	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00001401	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00007958	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00004684	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00003251	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00000967	29460056	DQ576492	piR-hsa-6740	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576492 may correlated with the increased risk of Azoospermia.
PIRP00008001	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00001655	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00006936	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00000353	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00006918	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00003566	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00002208	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00008984	29460056	DQ578561	piR-hsa-8802	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ578561 may correlated with the increased risk of Azoospermia.
PIRP00000425	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00000624	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00008678	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00002522	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00005864	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00002331	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00007037	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00004927	29460056	DQ570507	piR-hsa-787	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ570507 may correlated with the increased risk of Azoospermia.
PIRP00003825	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00001963	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00006354	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00008673	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00005481	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00003941	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00003457	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00001122	29460056	DQ579754	piR-hsa-10009	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ579754 may correlated with the increased risk of Azoospermia.
PIRP00004328	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00002462	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00006836	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00000098	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00005960	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00004460	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00003925	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00001608	29460056	DQ580288	piR-hsa-10528	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ580288 may correlated with the increased risk of Azoospermia.
PIRP00004734	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00002921	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00007245	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00000477	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00006434	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00004939	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00004318	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00002095	29460056	DQ589403	piR-hsa-19671	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ589403 may correlated with the increased risk of Azoospermia.
PIRP00001045	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00003758	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00009022	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00002502	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00008993	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00005663	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00004317	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00002091	29460056	DQ576926	piR-hsa-7247	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576926 may correlated with the increased risk of Azoospermia.
PIRP00000722	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00007954	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00003283	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00005614	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00002406	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00000844	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00000325	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00007211	29460056	DQ585544	piR-hsa-15839	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ585544 may correlated with the increased risk of Azoospermia.
PIRP00002457	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00000561	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00004991	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00007347	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00004088	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00002573	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00002070	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00008800	29460056	DQ594519	piR-hsa-24738	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ594519 may correlated with the increased risk of Azoospermia.
PIRP00006925	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00005163	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00000350	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00002739	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00008627	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00007055	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00006523	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00004292	29460056	DQ593632	piR-hsa-23880	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593632 may correlated with the increased risk of Azoospermia.
PIRP00001475	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00004208	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00000412	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00002951	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00000385	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00006197	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00004798	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00002531	29460056	DQ576170	piR-hsa-6433	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576170 may correlated with the increased risk of Azoospermia.
PIRP00005501	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00003627	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00008021	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00001281	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00007176	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00005618	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00005130	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00002816	29460056	DQ593864	piR-hsa-24112	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593864 may correlated with the increased risk of Azoospermia.
PIRP00006840	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00005081	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00000269	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00002643	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00008557	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00006983	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00006461	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00004219	29460056	DQ593626	piR-hsa-23874	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ593626 may correlated with the increased risk of Azoospermia.
PIRP00000476	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00007808	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00003034	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00005394	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00002247	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00000683	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00000087	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00006937	29460056	DQ598210	piR-hsa-28425	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ598210 may correlated with the increased risk of Azoospermia.
PIRP00002326	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00005059	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00001240	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00003750	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00001212	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00006935	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00005582	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00003354	29460056	DQ577970	piR-hsa-8229	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ577970 may correlated with the increased risk of Azoospermia.
PIRP00007135	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00005284	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00000556	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00002873	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00008767	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00007267	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00006729	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00004434	29460056	DQ596250	piR-hsa-26466	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ596250 may correlated with the increased risk of Azoospermia.
PIRP00008629	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00002319	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00007647	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00001030	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00007631	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00004215	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00002864	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00000584	29460056	DQ573385	piR-hsa-3678	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ573385 may correlated with the increased risk of Azoospermia.
PIRP00000093	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00002857	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00008132	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00001557	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00008104	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00004853	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00003418	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00001139	29460056	DQ576513	piR-hsa-6761	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ576513 may correlated with the increased risk of Azoospermia.
PIRP00001663	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00008826	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00004172	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00006509	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00003323	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00001786	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00001253	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00008020	29460056	DQ586061	piR-hsa-16311	Azoospermia	EFO:0000279	downregulation	increased risk	patients with nonobstructive azoospermia (NOA) between successful and unsuccessful sperm retrieval before micro-dissection testicular sperm extraction (micro-TESE)	N/A	N/A	Cell apoptosis, cell proliferation, and cell differentiation	-0.1	The piRNAs dysregulation associated with Azoospermia was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Azoospermia was validated by RT-PCR. The validated results indicated that the downregulation of DQ586061 may correlated with the increased risk of Azoospermia.
PIRP00007363	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00000965	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00006278	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00008780	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00002917	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00001510	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00008334	28826361	piR-31704	piR-hsa-1362	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-31704 may correlated with the increased risk of Idiopathic male infertility.
PIRP00006017	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00004226	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00008519	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00001821	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00006150	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00005628	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00003417	28826361	piR-39888	piR-hsa-32046	Idiopathic male infertility	EFO:0004248	upregulation	increased risk	sperm concentration and fertilization rate after ICSI	N/A	N/A	N/A	0.10	The piRNAs dysregulation associated with Idiopathic male infertility was screened by high throughput technologies such as next generation sequencing or microarray. And then the screened piRNAs dysregulation associated with Idiopathic male infertility was validated by RT-PCR. The validated results indicated that the upregulation of piR-39888 may correlated with the increased risk of Idiopathic male infertility.
PIRP00006442	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000084	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004038	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001984	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007032	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001313	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006690	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002622	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000086	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002887	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006804	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004573	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008458	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003609	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006153	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004636	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008150	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000278	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000085	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007023	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008845	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004363	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003124	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008434	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004754	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008710	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006740	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001415	27429044	hsa_piR_016946	piR-hsa-23621	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016946 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003707	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006510	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001381	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008359	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004378	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007782	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004020	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009021	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006514	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000182	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004157	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001921	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005751	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000931	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003507	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001975	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005506	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006724	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006513	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004373	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006219	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001707	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000441	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005807	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002088	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006063	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004013	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007856	27429044	hsa_piR_021190	piR-hsa-29417	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021190 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000344	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003198	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007062	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005079	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001032	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004433	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000594	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005713	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003202	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005871	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000792	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007689	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002424	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006698	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000133	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007729	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002181	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003420	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003201	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000936	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002904	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007401	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006196	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002470	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007746	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002653	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000662	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004522	27429044	hsa_piR_008033	piR-hsa-11256	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_008033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007950	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001696	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005565	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003561	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008584	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002934	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008177	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004221	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001699	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004461	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008371	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006159	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000890	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005223	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007749	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006202	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000646	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001898	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001698	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008579	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001364	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005859	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004730	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000946	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006307	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001157	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008239	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003009	27429044	hsa_piR_007336	piR-hsa-10246	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_007336 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006435	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000145	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004029	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002051	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007020	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001301	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006683	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002619	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000077	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002877	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006790	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004563	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008449	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003669	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006211	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004626	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008141	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000271	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000075	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007012	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008833	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004346	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003113	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008430	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004747	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008701	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006731	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001410	27429044	hsa_piR_020809	piR-hsa-28839	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020809 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007102	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000816	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004744	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002700	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007716	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002029	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007369	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003318	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000747	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003540	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007545	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005270	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000042	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004340	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006872	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005318	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008801	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000953	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000745	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007710	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000439	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005048	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003854	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000024	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005398	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000277	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007474	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002104	27429044	hsa_piR_016240	piR-hsa-22382	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_016240 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000652	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003863	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002355	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005598	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006043	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002472	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008978	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005745	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005969	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004452	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007759	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006474	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001198	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003390	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007489	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003345	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000057	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003451	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007973	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004238	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001465	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000709	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006149	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003696	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001243	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000056	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002010	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003381	27429044	hsa_piR_001042	piR-hsa-1338	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001042 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003753	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006566	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001349	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008415	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004426	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007833	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003989	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000013	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006569	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000162	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004205	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001978	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005809	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000989	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003554	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002040	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005558	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006756	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006568	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004419	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006272	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001687	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000486	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005848	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002059	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006040	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004058	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007907	27429044	hsa_piR_011901	piR-hsa-16348	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_011901 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003605	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006764	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005229	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008500	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008930	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005408	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002899	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008661	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008870	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007404	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001592	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000303	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004135	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006300	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001264	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006244	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003014	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006363	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001817	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007187	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004420	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003660	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009041	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006641	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004097	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003011	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004955	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006288	27429044	hsa_piR_005018	piR-hsa-7238	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005018 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000906	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004118	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002597	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005853	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006312	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002746	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000178	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006004	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006243	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004728	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008011	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006732	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001454	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003624	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007709	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003584	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000312	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003689	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008216	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004515	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001745	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000977	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006422	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003951	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001491	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000311	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002272	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003621	27429044	hsa_piR_001152	piR-hsa-1823	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_001152 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007649	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001312	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005242	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003218	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008240	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002575	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007854	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003872	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001317	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004087	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008036	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005813	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000543	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004869	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007423	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005852	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000284	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001522	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001316	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008236	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001037	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005520	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004359	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000596	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005941	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000859	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007923	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002652	27429044	hsa_piR_017295	piR-hsa-24143	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017295 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008809	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002568	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006446	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004444	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000391	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003727	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009029	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005120	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002572	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005283	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000175	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007042	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001798	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006064	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008589	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007084	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001524	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002697	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002570	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000308	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002201	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006739	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005587	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001843	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007116	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002055	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000038	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003890	27429044	hsa_piR_019102	piR-hsa-26441	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019102 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003606	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006765	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005233	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008502	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008931	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005410	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002902	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008662	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008875	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007407	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001594	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000304	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004137	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006302	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001267	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006246	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003016	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006364	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001820	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007189	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004421	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003661	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009043	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006642	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004100	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003015	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004958	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006290	27429044	hsa_piR_005019	piR-hsa-7239	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_005019 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005342	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008127	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003003	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000897	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005962	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000256	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005623	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001576	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008131	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001813	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005764	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003537	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007390	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002557	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005119	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003581	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007113	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008307	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008130	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005949	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007844	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003321	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002093	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007468	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003668	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007701	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005617	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000349	27429044	hsa_piR_021214	piR-hsa-29114	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_021214 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001605	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004442	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008282	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006297	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002288	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005655	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001858	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006964	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004445	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007126	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002083	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008860	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003656	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007932	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001387	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008903	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003433	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004560	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004443	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002207	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004114	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008581	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007508	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003700	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008922	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003901	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001927	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005744	27429044	hsa_piR_012681	piR-hsa-17444	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_012681 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005505	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008296	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003116	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001119	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006165	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000379	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005742	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001784	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008298	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001940	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005940	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003706	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007609	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002763	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005323	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003752	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007318	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008431	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008297	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006082	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007945	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003445	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002275	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007645	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003782	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007814	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005817	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000536	27429044	hsa_piR_019201	piR-hsa-26570	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019201 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005143	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007939	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002743	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000696	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005782	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000005	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005374	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001375	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007942	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001527	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005574	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003350	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007180	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002377	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004943	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003401	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006907	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008061	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007941	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005685	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007618	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003049	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001869	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007233	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003430	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007459	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005434	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000149	27429044	hsa_piR_019168	piR-hsa-26527	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019168 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003897	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006713	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001490	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008556	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004552	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007892	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004134	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000143	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006716	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000290	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004348	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002114	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005927	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001135	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003683	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002164	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005677	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006835	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006715	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004486	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006342	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001812	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000633	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005973	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002193	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006188	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004198	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008025	27429044	hsa_piR_019420	piR-hsa-26872	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_019420 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004635	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007504	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002254	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000197	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005316	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008652	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004892	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000870	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007509	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001125	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005098	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002848	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006677	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001864	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004415	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002900	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006424	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007680	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007507	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005308	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007148	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002547	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001356	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006712	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002978	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006908	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004968	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008747	27429044	hsa_piR_017791	piR-hsa-24775	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017791 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008295	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002085	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005999	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003919	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008928	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003310	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008613	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004594	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002090	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004846	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008756	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006511	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001333	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005568	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008099	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006565	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001043	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002279	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002087	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008925	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001754	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006311	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005099	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001304	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006684	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001593	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008684	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003410	27429044	hsa_piR_017061	piR-hsa-23822	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017061 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005915	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008732	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003549	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001503	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006491	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000806	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006170	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002134	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008654	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002372	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006308	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004050	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007974	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003179	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005700	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004096	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007683	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008842	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008651	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006487	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008335	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003845	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002602	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007949	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004201	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008195	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006225	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000887	27429044	hsa_piR_020450	piR-hsa-28319	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020450 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003373	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006100	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000947	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007968	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003938	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007359	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003603	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008607	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006104	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008825	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003726	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001473	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005406	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000495	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003071	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001517	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005102	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006306	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006101	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003932	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005795	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001259	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000016	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005384	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001639	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005630	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003663	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007484	27429044	hsa_piR_017033	piR-hsa-23786	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_017033 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007697	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001397	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005313	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003285	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008305	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002630	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007924	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003936	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001405	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004083	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008112	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005870	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000618	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004948	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007522	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005914	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000363	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001520	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001400	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008233	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001111	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005589	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004430	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000665	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005939	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000855	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007984	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002738	27429044	hsa_piR_014620	piR-hsa-20266	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_014620 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006562	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000288	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004183	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002192	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007185	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001461	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006807	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002798	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000223	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003007	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006955	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004749	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008595	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003823	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006376	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004789	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008276	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000427	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000221	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007179	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008966	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004508	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003278	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008575	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004885	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008829	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006875	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001552	27429044	hsa_piR_020814	piR-hsa-28850	Hepatocellular carcinoma	EFO:0000182	downregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	-0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the downregulation of hsa_piR_020814 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001670	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004484	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008322	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006350	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002337	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005702	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001910	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007011	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004488	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007186	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002121	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008902	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003699	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007982	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001431	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008939	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003476	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004697	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004485	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002266	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004166	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008628	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007555	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003744	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008974	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003945	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001983	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005796	27429044	hsa_piR_018165	piR-hsa-25313	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_018165 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006537	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000262	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004160	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002174	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007166	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001443	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006767	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002777	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000201	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002987	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006929	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004710	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008576	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003799	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006348	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004772	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008262	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000405	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000196	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007156	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008941	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004474	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003255	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008555	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004868	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008817	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006851	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001518	27429044	hsa_piR_020499	piR-hsa-28398	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020499 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006733	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000457	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004358	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002361	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007353	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001657	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006993	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002949	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000393	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003186	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007128	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004909	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008776	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003972	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006508	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004964	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008442	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000593	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000392	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007349	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000079	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004678	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003449	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008749	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005057	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008987	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007053	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001730	27429044	hsa_piR_020829	piR-hsa-28877	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020829 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002801	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005599	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000368	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007528	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003396	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006748	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003030	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008047	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005602	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008267	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003171	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000889	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004848	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000002	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002562	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000944	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004567	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005723	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005536	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003388	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005245	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000680	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008582	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004823	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001071	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005092	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003086	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006911	27429044	hsa_piR_019951	piR-hsa-27140	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019951 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004592	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007476	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002220	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000168	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005214	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008552	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004865	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000763	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007368	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001012	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004990	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002742	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006650	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001829	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004385	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002794	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006313	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007602	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007366	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005212	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007036	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002521	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001261	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006612	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002894	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006866	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004941	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008630	27429044	hsa_piR_020365	piR-hsa-28190	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020365 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003959	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006762	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001565	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008624	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004554	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007953	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004209	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000144	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006719	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000371	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004353	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002117	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006008	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001200	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003748	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002169	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005678	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006917	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006717	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004551	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006418	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001894	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000636	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005980	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002273	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006256	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004278	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008028	27429044	hsa_piR_020305	piR-hsa-28117	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020305 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000804	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004016	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002506	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005748	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006205	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002618	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000081	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005901	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006144	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004600	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007921	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006653	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001342	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003536	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007634	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003484	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000212	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003594	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008119	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004407	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001648	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000864	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006310	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003860	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001395	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000211	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002159	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003530	27429044	hsa_piR_001205	piR-hsa-1359	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001205 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004629	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007836	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006285	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000445	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000900	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006425	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003896	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000604	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000836	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008353	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002612	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001325	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005191	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007336	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002315	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007281	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004022	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007409	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002860	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008170	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005439	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004693	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001015	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007684	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005232	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004021	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005926	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007328	27429044	hsa_piR_000823	piR-hsa-1282	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000823 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001555	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004404	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008235	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006242	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002171	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005553	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001809	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006831	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004405	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007077	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001955	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008764	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003615	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007896	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001326	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008806	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003382	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004528	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004323	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002160	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003995	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008530	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007438	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003597	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008883	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003858	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001877	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005687	27429044	hsa_piR_019824	piR-hsa-27492	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019824 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008947	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002759	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006609	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004609	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000481	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003900	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000141	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005228	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002666	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005431	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000266	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007147	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001971	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006227	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008769	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007206	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001646	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002890	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002664	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000475	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002378	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006912	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005662	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001949	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007306	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002229	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000204	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003973	27429044	hsa_piR_023057	piR-hsa-31766	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_023057 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007672	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001746	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000120	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003488	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003929	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000320	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006901	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003631	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003868	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002340	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005625	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004368	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008155	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001237	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005336	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001185	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007043	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001287	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005847	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002127	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008418	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007717	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004024	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001569	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008133	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007041	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008908	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001230	27429044	hsa_piR_004987	piR-hsa-7193	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004987 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008242	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002028	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005865	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003865	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008877	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003257	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008481	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004537	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002033	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004792	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008697	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006466	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001220	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005504	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008032	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006495	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000957	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002225	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002031	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008869	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001703	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006181	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005045	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001266	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006616	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001456	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008550	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003347	27429044	hsa_piR_017724	piR-hsa-24684	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_017724 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002973	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005788	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000564	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007686	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003562	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006943	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003230	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008228	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005791	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008451	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003369	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001118	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005044	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000181	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002776	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001150	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004791	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005908	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005708	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003560	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005419	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000862	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008786	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005011	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001245	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005282	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003294	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007111	27429044	hsa_piR_019914	piR-hsa-27622	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019914 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005826	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008963	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007552	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001684	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002133	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007665	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005114	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001900	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002074	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000487	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003829	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002556	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006371	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008493	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003505	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008445	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005267	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008619	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004102	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000359	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006647	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005874	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002317	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008822	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006411	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005266	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007164	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008484	27429044	hsa_piR_004309	piR-hsa-6147	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_004309 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006668	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000682	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008229	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002510	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002909	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008349	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005854	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002649	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002839	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001263	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004668	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003344	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007213	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000172	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004262	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000122	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005979	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000300	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004903	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001138	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007443	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006656	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003062	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000509	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007183	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005978	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007914	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000167	27429044	hsa_piR_003728	piR-hsa-5370	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_003728 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006535	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000259	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004158	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002168	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007162	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001440	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006763	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002773	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000193	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002982	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006927	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004704	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008574	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003791	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006344	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004770	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008257	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000399	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000192	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007151	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008937	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004472	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003252	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008549	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004863	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008815	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006847	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001516	27429044	hsa_piR_020498	piR-hsa-28395	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020498 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001385	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004214	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008079	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006072	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002004	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005390	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001644	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006737	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004217	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006893	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001851	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008585	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003467	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007738	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001170	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008632	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003197	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004345	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004143	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001996	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003842	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008358	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007243	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003442	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008745	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003688	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001713	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005541	27429044	hsa_piR_013306	piR-hsa-18287	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_013306 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006688	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000318	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004285	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002235	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007285	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001568	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006922	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002901	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000323	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003106	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007060	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004840	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008708	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003847	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006407	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004889	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008370	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000528	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000319	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007277	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000019	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004597	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003385	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008679	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004984	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008915	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006996	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001677	27429044	hsa_piR_016970	piR-hsa-23655	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016970 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003780	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006602	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001450	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008443	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004457	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007852	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004085	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000033	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006607	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000253	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004237	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002013	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005833	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001020	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003580	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002054	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005581	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006781	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006603	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004451	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006301	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001782	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000512	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005869	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002146	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006143	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004080	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007926	27429044	hsa_piR_010894	piR-hsa-15023	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010894 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004529	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007360	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002142	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000097	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005128	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008475	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004790	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000694	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007288	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000929	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004933	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002646	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006551	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001762	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004300	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002699	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006233	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007539	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007284	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005121	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006957	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002450	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001188	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006525	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002819	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006784	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004854	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008565	27429044	hsa_piR_020363	piR-hsa-28185	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020363 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004527	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007358	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002137	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000096	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005125	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008472	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004786	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000692	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007283	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000924	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004928	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002642	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006547	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001756	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004298	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002695	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006228	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007534	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007282	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005115	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006954	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002448	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001184	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006522	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002817	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006780	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004852	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008561	27429044	hsa_piR_020362	piR-hsa-28183	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020362 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004408	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007237	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002036	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009035	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005007	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008348	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004650	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000577	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007170	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000800	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004808	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002542	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006445	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001638	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004178	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002582	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006122	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007376	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007169	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005001	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006825	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002332	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001089	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006426	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002673	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006695	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004739	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008438	27429044	hsa_piR_020657	piR-hsa-28629	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020657 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006744	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000402	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004375	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002310	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007373	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001669	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007005	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002962	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000406	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003192	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007150	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004926	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008785	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003918	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006465	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004972	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008453	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000611	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000404	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007362	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000092	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004688	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003464	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008759	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005072	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00009001	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007066	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001744	27429044	hsa_piR_016975	piR-hsa-23663	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016975 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004530	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007361	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002143	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000099	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005129	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008476	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004795	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000695	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007290	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000930	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004936	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002648	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006552	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001764	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004301	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002704	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006235	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007540	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007287	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005123	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006960	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002451	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001190	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006526	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002822	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006789	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004856	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008566	27429044	hsa_piR_020364	piR-hsa-28186	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020364 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003971	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006769	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001583	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008636	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004653	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007966	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004222	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000226	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006776	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000384	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004441	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002200	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006019	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001210	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003761	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002259	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005775	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006926	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006772	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004562	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006429	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001904	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000713	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006067	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002278	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006267	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004289	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008109	27429044	hsa_piR_009051	piR-hsa-12487	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_009051 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006730	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000454	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004357	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002359	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007352	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001651	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006991	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002945	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000390	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003183	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007124	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004902	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008771	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003969	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006506	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004960	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008437	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000591	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000389	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007344	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000076	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004671	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003446	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008748	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005054	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008983	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007051	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001728	27429044	hsa_piR_020828	piR-hsa-28875	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020828 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005322	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007149	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002534	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004244	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002716	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003128	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003477	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000208	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002228	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008013	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000799	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008303	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007798	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006485	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008890	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008164	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001623	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003582	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004887	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001445	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005515	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007766	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004002	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004362	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004800	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002868	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008174	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005451	27429044	hsa_piR_000291	piR-hsa-624	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_000291 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002465	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005307	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000048	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007070	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003060	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006444	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002694	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007748	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005239	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007967	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002854	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000573	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004518	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008689	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002265	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000629	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004175	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005416	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005238	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003054	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004930	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000351	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008199	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004481	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000719	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004773	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002790	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006501	27429044	hsa_piR_016664	piR-hsa-23216	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_016664 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008529	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002321	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006174	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004159	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000055	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003478	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008791	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004794	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002325	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005010	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008898	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006703	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001502	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005806	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008319	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006736	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001265	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002447	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002252	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000044	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001930	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006473	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005340	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001489	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006830	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001781	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008837	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003620	27429044	hsa_piR_020009	piR-hsa-27730	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_020009 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001103	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004284	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002786	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006015	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006472	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002911	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000347	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006176	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006420	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004891	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008162	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006895	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001634	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003787	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007858	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003733	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000474	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003849	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008365	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004679	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001914	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001151	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006561	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004117	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001685	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000473	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002426	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003778	27429044	hsa_piR_001170	piR-hsa-1849	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_001170 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008991	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003167	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001539	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004916	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005352	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001759	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008290	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005074	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005305	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003721	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007044	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005766	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000468	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002641	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006710	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002601	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008421	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002722	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007272	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003538	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000749	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000001	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005450	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002995	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000447	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008420	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001271	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002632	27429044	hsa_piR_005076	piR-hsa-7327	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_005076 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003460	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006250	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001053	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008103	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004077	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007478	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003675	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008766	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006253	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008897	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003886	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001643	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005486	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000656	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003237	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001692	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005259	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006393	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006252	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004006	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005863	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001324	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000157	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005527	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001721	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005716	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003734	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007628	27429044	hsa_piR_019368	piR-hsa-26819	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019368 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001551	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004399	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008232	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006239	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002167	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005551	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001806	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006829	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004403	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007073	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001953	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008762	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003611	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007895	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001323	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008804	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003380	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004525	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00004316	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002156	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003991	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008526	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007432	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003596	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008879	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003853	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001874	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005684	27429044	hsa_piR_019822	piR-hsa-27490	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_019822 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005428	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008225	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003050	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001027	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006005	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000292	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005657	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001622	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008227	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00001855	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005808	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003564	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007538	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002661	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005240	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003610	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007240	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008344	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00008160	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00006001	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007873	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003359	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00002188	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007510	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00003702	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00007736	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00005725	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.
PIRP00000456	27429044	hsa_piR_010155	piR-hsa-13940	Hepatocellular carcinoma	EFO:0000182	upregulation	increased risk	Hepatocellular carcinoma_vs_Cirrhosis	N/A	N/A	N/A	0.05	The piRNAs dysregulation associated with Hepatocellular carcinoma was screened by high throughput technologies such as next generation sequencing or microarray. The screened results indicated that the upregulation of hsa_piR_010155 may correlated with the increased risk of Hepatocellular carcinoma.